

Inhaling medicines: delivering drugs to the body through

Nature Reviews Drug Discovery

6, 67-74

DOI: 10.1038/nrd2153

Citation Report

#	ARTICLE	IF	CITATIONS
1	Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1138-1145.	5.6	74
2	Highlights and Book Reviews. Journal of Clinical Pharmacology, 2007, 47, 1055-1060.	2.0	1
3	Inhalation, Deposition, and Fate of Insulin and Other Therapeutic Proteins. Diabetes Technology and Therapeutics, 2007, 9, S-4-S-15.	4.4	59
4	Nanoparticles for drug delivery to the lungs. Trends in Biotechnology, 2007, 25, 563-570.	9.3	549
5	In vivo animal models for drug delivery across the lung mucosal barrier. Advanced Drug Delivery Reviews, 2007, 59, 1133-1151.	13.7	132
6	Pharmaceutical Particle Engineering via Spray Drying. Pharmaceutical Research, 2008, 25, 999-1022.	3.5	1,308
7	Aerodynamical, Immunological and Pharmacological Properties of the Anticancer Antibody Cetuximab Following Nebulization. Pharmaceutical Research, 2008, 25, 1318-1326.	3.5	51
8	Molecular and Functional Expression of Multidrug Resistance-Associated Protein-1 in Primary Cultured Rat Alveolar Epithelial Cells. Journal of Pharmaceutical Sciences, 2008, 97, 2340-2349.	3.3	9
9	Inhaled nanoparticles—A current review. International Journal of Pharmaceutics, 2008, 356, 239-247.	5.2	560
10	High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. International Journal of Pharmaceutics, 2008, 361, 177-188.	5.2	106
11	ACCELERATED DOSING FREQUENCY OF A PULMONARY FORMULATION OF TISSUE PLASMINOGEN ACTIVATOR IS WELL-TOLERATED IN MICE. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 1454-1460.	1.9	9
12	Cell-penetrating and cell-targeting peptides in drug delivery. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1786, 126-138.	7.4	274
13	Discovery of tight junction modulators: significance for drug development and delivery. Drug Discovery Today, 2008, 13, 261-267.	6.4	34
14	Efficacy of pulmonary insulin delivery in diabetic rats: Use of a model-based approach in the evaluation of insulin powder formulations. Journal of Controlled Release, 2008, 127, 257-266.	9.9	35
15	Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opinion on Drug Delivery, 2008, 5, 629-639.	5.0	224
17	Characterization of protein factor(s) in rat bronchoalveolar lavage fluid that enhance insulin transport via transcytosis across primary rat alveolar epithelial cell monolayers. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 808-816.	4.3	8
18	Quality by design – Spray drying of insulin intended for inhalation. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 828-838.	4.3	117
19	Pulmonary applications and toxicity of engineered nanoparticles. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L400-L411.	2.9	245

#	ARTICLE	IF	CITATIONS
20	Short Inhalation Exposures of the Isolated and Perfused Rat Lung to Respirable Dry Particle Aerosols; the Detailed Pharmacokinetics of Budesonide, Formoterol, and Terbutaline. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 169-180.	1.4	22
21	Inhaled Insulin: Take a Deep Breath, but How?. Journal of Diabetes Science and Technology, 2008, 2, 297-299.	2.2	3
22	Delivery of Contraceptives to Men: Lesson from Other Therapeutic Drugs. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2008, 8, 91-94.	0.5	3
23	Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics: Targets and Therapy, 0, , 193.	3.2	34
25	Inhaled Carbenoxolone Prevents Allergic Airway Inflammation and Airway Hyperreactivity in a Mouse Model of Asthma. International Archives of Allergy and Immunology, 2009, 149, 38-46.	2.1	20
26	Oral inhalation therapy: meeting the challenge of developing more patient-appropriate devices. Expert Review of Medical Devices, 2009, 6, 147-155.	2.8	13
27	Technosphere® Insulin: Defining the Role of Technosphere Particles at the Cellular Level. Journal of Diabetes Science and Technology, 2009, 3, 545-554.	2.2	64
28	NO- and Haem-Independent Soluble Guanylate Cyclase Activators. Handbook of Experimental Pharmacology, 2009, , 309-339.	1.8	131
29	Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: In vivo deposition and hypoglycaemic activity after delivery to rat lungs. Journal of Controlled Release, 2009, 135, 25-34.	9.9	158
30	Sparing methylation of Î²-cyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers in vitro. Journal of Controlled Release, 2009, 136, 110-116.	9.9	60
31	Absorption of Polyethylene Glycol (PEG) Polymers: The Effect of PEG Size on Permeability. Journal of Pharmaceutical Sciences, 2009, 98, 2847-2856.	3.3	55
32	Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. Journal of Pharmaceutical Sciences, 2009, 98, 2875-2885.	3.3	65
33	Nanoparticle formulations in pulmonary drug delivery. Medicinal Research Reviews, 2009, 29, 196-212.	10.5	257
34	Templated Open Flocs of Nanorods for Enhanced Pulmonary Delivery with Pressurized Metered Dose Inhalers. Pharmaceutical Research, 2009, 26, 101-117.	3.5	41
35	The Pharmacokinetics and Bioavailability of Prochlorperazine Delivered as a Thermally Generated Aerosol in a Single Breath to Volunteers. Clinical Pharmacology and Therapeutics, 2009, 85, 71-77.	4.7	21
36	A functional model for adult stem cells in epithelial tissues. Wound Repair and Regeneration, 2009, 17, 296-305.	3.0	24
37	Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. International Journal of Pharmaceutics, 2009, 369, 136-143.	5.2	65
38	Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. International Journal of Pharmaceutics, 2009, 366, 218-220.	5.2	27

#	ARTICLE	IF	CITATIONS
39	Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles. International Journal of Pharmaceutics, 2009, 369, 176-184.	5.2	16
40	Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials, 2009, 30, 1947-1953.	11.4	235
41	Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regulatory Peptides, 2009, 152, 101-107.	1.9	36
42	Preclinical models for pulmonary drug delivery. Expert Opinion on Drug Delivery, 2009, 6, 1231-1245.	5.0	101
43	Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet?. Journal of Chemical Information and Modeling, 2009, 49, 1025-1032.	5.4	58
44	Measurement of Lateral Adhesion Forces at the Interface between a Liquid Drop and a Substrate. Physical Review Letters, 2009, 103, 266101.	7.8	205
45	Nanomedicine in pulmonary delivery. International Journal of Nanomedicine, 2009, 4, 299.	6.7	378
46	Mechanism of Insulin Uptake in Rat Alveolar Type II and Type I-Like Epithelial Cells. Biological and Pharmaceutical Bulletin, 2009, 32, 1765-1769.	1.4	17
47	Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. European Journal of Medical Research, 2009, 14, 71.	2.2	53
48	Effect of Particle Formulation on Dry Powder Inhalation Efficiency. Current Pharmaceutical Design, 2010, 16, 2377-2387.	1.9	31
49	Problems and Examples of Biomolecule Inhalation for Systemic Treatment. , 2010, , 67-76.		0
50	Isoxyl Aerosols for Tuberculosis Treatment: Preparation and Characterization of Particles. AAPS PharmSciTech, 2010, 11, 538-549.	3.3	27
51	Chitosan-based delivery systems for protein therapeutics and antigens. Advanced Drug Delivery Reviews, 2010, 62, 59-82.	13.7	564
52	Development of inhalable dry powder formulation of basic fibroblast growth factor. International Journal of Pharmaceutics, 2010, 385, 66-72.	5.2	21
53	Investigation of the dynamic process during spray-drying to improve aerodynamic performance of inhalation particles. International Journal of Pharmaceutics, 2010, 390, 250-259.	5.2	40
54	Cell-Based Multiscale Computational Modeling of Small Molecule Absorption and Retention in the Lungs. Pharmaceutical Research, 2010, 27, 457-467.	3.5	22
55	Inhalation Performance of Physically Mixed Dry Powders Evaluated with a Simple Simulator for Human Inspiratory Flow Patterns. Pharmaceutical Research, 2010, 27, 2131-2140.	3.5	15
56	Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. Journal of Controlled Release, 2010, 144, 233-241.	9.9	197

#	ARTICLE	IF	CITATIONS
57	In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 336-347.	4.0	44
58	Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 60-70.	4.0	55
59	Non-invasive Systemic Drug Delivery: Developability Considerations for Alternate Routes of Administration. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 1-20.	3.3	126
60	One-step preparation of chitosan solid nanoparticles by electrospray deposition. <i>International Journal of Pharmaceutics</i> , 2010, 397, 211-217.	5.2	149
61	Meeting Acute Migraine Treatment Needs through Novel Treatment Formulations. <i>Neurotherapeutics</i> , 2010, 7, 153-158.	4.4	7
62	PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. <i>Toxicology</i> , 2010, 278, 256-267.	4.2	155
63	The potential for the noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the treatment of Chlamydial respiratory infections. <i>Biomaterials</i> , 2010, 31, 7376-7385.	11.4	31
64	The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 271-278.	2.4	9
65	Technological Requirements for Inhalation of Biomolecule Aerosols. , 2010, , 60-66.		2
66	Inhaled insulin: overview of a novel route of insulin administration. <i>Vascular Health and Risk Management</i> , 2010, 6, 47.	2.3	48
67	Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retrospective. <i>Drug Development and Industrial Pharmacy</i> , 2010, 36, 31-44.	2.0	19
69	Differential Effects of Insufflated, Subcutaneous, and Intravenous Growth Hormone on Bone Growth, Cognitive Function, and NMDA Receptor Subunit Expression. <i>Endocrinology</i> , 2010, 151, 4418-4427.	2.8	11
70	Controllable electrosprayed nanoparticles for quantitative characterization and exposure protocol. , 2010, , .		0
71	Pulmonary Drug Delivery: Medicines for Inhalation. <i>Handbook of Experimental Pharmacology</i> , 2010, , 171-192.	1.8	22
72	The Particle has Landedâ€”Characterizing the Fate of Inhaled Pharmaceuticals. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, S-71-S-87.	1.4	191
73	Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 75, 33-41.	4.3	119
74	Semifluorinated alkanes â€” A new class of excipients suitable for pulmonary drug delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 76, 75-82.	4.3	22
75	Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. <i>Drug Development and Industrial Pharmacy</i> , 2010, 36, 1-30.	2.0	54

#	ARTICLE	IF	CITATIONS
76	The Identification of Indacaterol as an Ultralong-Acting Inhaled β_2 -Adrenoceptor Agonist. Journal of Medicinal Chemistry, 2010, 53, 3675-3684.	6.4	90
77	Miniaturized multiple Fourier-horn ultrasonic droplet generators for biomedical applications. Lab on A Chip, 2010, 10, 2733.	6.0	21
78	An In Vivo Experiment to Improve Pulmonary Absorption of Insulin Using Microbubbles. Diabetes Technology and Therapeutics, 2011, 13, 1013-1021.	4.4	2
79	Swellable Hydrogel Particles for Controlled Release Pulmonary Administration Using Propellant-Driven Metered Dose Inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2011, 24, 25-34.	1.4	29
80	MEMS-based multiple fourier-horn silicon ultrasonic atomizer for inhalation drug delivery. , 2011, , .		1
81	Nanoparticle-Stabilized Colloids in Compressible Hydrofluoroalkanes. Langmuir, 2011, 27, 10501-10506.	3.5	5
82	Emerging functional nanomaterials for therapeutics. Journal of Materials Chemistry, 2011, 21, 13107.	6.7	148
83	The Delivery of Drugs “ Peptides and Proteins. , 2011, , 587-604.		7
84	Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Therapeutic Delivery, 2011, 2, 1057-1077.	2.2	116
85	Biodegradable Nanoparticles Meet the Bronchial Airway Barrier: How Surface Properties Affect Their Interaction with Mucus and Epithelial Cells. Biomacromolecules, 2011, 12, 4136-4143.	5.4	91
86	Synthesis of leucine micro/nanocrystals for pharmaceutical applications. CrystEngComm, 2011, 13, 6157.	2.6	2
87	Particle Engineering Technologies for Pulmonary Drug Delivery. , 2011, , 283-312.		5
88	Toxicology of Nanomaterials Used in Nanomedicine. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2011, 14, 593-632.	6.5	239
89	Pulmonary Drug Metabolism, Clearance, and Absorption. , 2011, , 21-50.		91
90	The influence of pulmonary surfactant on nanoparticulate drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 350-352.	4.3	51
91	Human growth hormone: New delivery systems, alternative routes of administration, and their pharmacological relevance. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 278-288.	4.3	32
92	Overcoming Lung Clearance Mechanisms for Controlled Release Drug Delivery. , 2011, , 101-126.		14
93	Macro- and Microstructure of the Airways for Drug Delivery. , 2011, , 1-19.		3

#	ARTICLE	IF	CITATIONS
94	Science and Technology of Pressurized Metered-Dose Inhalers. , 2011, , 165-201.		5
95	What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?. Future Medicinal Chemistry, 2011, 3, 1635-1645.	2.3	21
96	Development of a stochastic individual path (SIP) model for predicting the tracheobronchial deposition of pharmaceutical aerosols: Effects of transient inhalation and sampling the airways. Journal of Aerosol Science, 2011, 42, 781-799.	3.8	88
97	Opportunities and challenges of the pulmonary route for vaccination. Expert Opinion on Drug Delivery, 2011, 8, 547-563.	5.0	50
98	Cell Culture Systems for Studying Biomaterial Interactions with Biological Barriers. , 2011, , 193-214.		1
99	Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. International Journal of Nanomedicine, 2011, 6, 2591.	6.7	108
100	Pharmacokinetics of opioids. , 0, , 509-530.		2
101	Convective flow dominates aerosol delivery to the lung segments. Journal of Applied Physiology, 2011, 111, 48-54.	2.5	35
102	Pulmonary Delivery: Innovative Approaches and Perspectives. Journal of Biomaterials and Nanobiotechnology, 2011, 02, 567-575.	0.5	25
103	Toxicology and clinical potential of nanoparticles. Nano Today, 2011, 6, 585-607.	11.9	558
104	Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. Journal of Controlled Release, 2011, 152, 370-375.	9.9	44
105	Nebulizer Delivery of Micafungin Aerosols. Pharmacotherapy, 2011, 31, 52-57.	2.6	3
106	Supercritical fluid assisted atomization introduced by an enhanced mixer for micronization of lysozyme: Particle morphology, size and protein stability. International Journal of Pharmaceutics, 2011, 421, 258-268.	5.2	34
107	Physicochemical Characterization and Water Vapor Sorption of Organic Solution Advanced Spray-Dried Inhalable Trehalose Microparticles and Nanoparticles for Targeted Dry Powder Pulmonary Inhalation Delivery. AAPS PharmSciTech, 2011, 12, 1420-1430.	3.3	34
108	Toward managing chronic rejection after lung transplant: The fate and effects of inhaled cyclosporine in a complex environment. Advanced Drug Delivery Reviews, 2011, 63, 88-109.	13.7	10
109	Formation, characterization, and fate of inhaled drug nanoparticles. Advanced Drug Delivery Reviews, 2011, 63, 441-455.	13.7	175
110	Challenges in inhaled product development and opportunities for open innovation. Advanced Drug Delivery Reviews, 2011, 63, 69-87.	13.7	95
111	Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Advanced Drug Delivery Reviews, 2011, 63, 1118-1159.	13.7	416

#	ARTICLE	IF	CITATIONS
112	The Rule of Five for Non-Oral Routes of Drug Delivery: Ophthalmic, Inhalation and Transdermal. <i>Pharmaceutical Research</i> , 2011, 28, 943-948.	3.5	148
113	Formation of Protein Nano-Matrix Particles with Controlled Surface Architecture for Respiratory Drug Delivery. <i>Pharmaceutical Research</i> , 2011, 28, 788-796.	3.5	35
114	Inhalable Sustained-Release Formulation of Glucagon: In Vitro Amyloidogenic and Inhalation Properties, and In Vivo Absorption and Bioactivity. <i>Pharmaceutical Research</i> , 2011, 28, 1157-1166.	3.5	17
115	Albumin-Coated Porous Hollow Poly(Lactic-co-Glycolic Acid) Microparticles Bound with Palmityl-Acylated Exendin-4 as a Long-Acting Inhalation Delivery System for the Treatment of Diabetes. <i>Pharmaceutical Research</i> , 2011, 28, 2008-2019.	3.5	45
116	The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. <i>Pharmaceutical Research</i> , 2011, 28, 2147-2156.	3.5	64
117	Lung vascular targeting through inhalation delivery: Insight from filamentous viruses and other shapes. <i>IUBMB Life</i> , 2011, 63, 607-612.	3.4	27
118	Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. <i>Biomaterials</i> , 2011, 32, 1685-1693.	11.4	88
119	Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2011, 409, 156-163.	5.2	145
120	Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R15, 20, 21, L17, A24,25, des-N28]-VIP-GRR) in experimental asthma/COPD model rats. <i>International Journal of Pharmaceutics</i> , 2011, 410, 54-60.	5.2	15
121	Third-generation long-acting β_2 -adrenoceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled β_2 -adrenoceptor agonists. <i>Future Medicinal Chemistry</i> , 2011, 3, 1607-1622.	2.3	14
122	Seizure Protection by Intrapulmonary Delivery of Propofol Hemisuccinate. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 215-222.	2.5	15
123	A Highly Automated Assay for Determining the Aqueous Equilibrium Solubility of Drug Discovery Compounds. <i>Journal of the Association for Laboratory Automation</i> , 2011, 16, 276-284.	2.8	24
124	Aerosol deposition characteristics in distal acinar airways under cyclic breathing conditions. <i>Journal of Applied Physiology</i> , 2011, 110, 1271-1282.	2.5	57
125	Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis of Proteolytic Enzymes in Cultures of Human Respiratory Epithelial Cells. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2011, 24, 89-101.	1.4	26
126	DNA and RNA delivery to the lungs using polymers. <i>Journal of Drug Delivery Science and Technology</i> , 2011, 21, 323-330.	3.0	1
127	Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models. <i>Journal of Nanomaterials</i> , 2011, 2011, 1-16.	2.7	26
128	A Cell-based Computational Modeling Approach for Developing Site-Directed Molecular Probes. <i>PLoS Computational Biology</i> , 2012, 8, e1002378.	3.2	7
129	Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and Other Pharmaceutical Applications. <i>Journal of Drug Delivery</i> , 2012, 2012, 1-10.	2.5	52

#	ARTICLE	IF	CITATIONS
130	Interaction and Localization of Synthetic Nanoparticles in Healthy and Cystic Fibrosis Airway Epithelial Cells: Effect of Ozone Exposure. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 7-15.	1.4	13
131	Ejection of Uniform Micrometer-Sized Droplets from Faraday Waves on a Millimeter-Sized Water Drop. Physical Review Letters, 2012, 108, 154501.	7.8	17
132	The Direct Effect of Hyperosmolar Agents on Ciliary Beating of Human Bronchial Epithelial Cells. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 88-95.	1.4	17
133	Hand-held high-throughput ultrasonic monodisperse aerosol inhalers for detoxification of massive cyanide poisoning. , 2012, , .		2
135	Trough Insulin Levels in Bronchoalveolar Lavage Following Inhaled Human Insulin (Exubera) in Patients with Diabetes Mellitus. Diabetes Technology and Therapeutics, 2012, 14, 50-58.	4.4	4
136	Nanoparticle delivery in infant lungs. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5092-5097.	7.1	58
137	Micrometer-sized droplet ejection from a millimeter-sized spherical water drop using a megahertz multiple-fourier horn ultrasonic nozzle. , 2012, , .		0
138	Enhancement Effect of Poly(amino acid)s on Insulin Uptake in Alveolar Epithelial Cells. Drug Metabolism and Pharmacokinetics, 2012, 27, 570-578.	2.2	5
140	Human epithelial cells in vitro “Are they an advantageous tool to help understand the nanomaterial-biological barrier interaction?. EURO-NanoTox-Letters, 2012, 4, 1-19.	1.0	22
141	Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. Journal of Pharmacy and Pharmacology, 2012, 64, 1217-1235.	2.4	154
142	Inhaled Fentanyl Aerosol in Healthy Volunteers. Anesthesia and Analgesia, 2012, 115, 1071-1077.	2.2	40
143	Modification of Disodium Cromoglycate Passage Across Lung Epithelium In Vitro Via Incorporation into Polymeric Microparticles. AAPS Journal, 2012, 14, 79-86.	4.4	4
144	Design of Experiments-Based Monitoring of Critical Quality Attributes for the Spray-Drying Process of Insulin by NIR Spectroscopy. AAPS PharmSciTech, 2012, 13, 747-755.	3.3	26
145	Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy. Acta Diabetologica, 2012, 49, 315-325.	2.5	56
146	Magnetised Thermo Responsive Lipid Vehicles for Targeted and Controlled Lung Drug Delivery. Pharmaceutical Research, 2012, 29, 2456-2467.	3.5	47
147	Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice. Regulatory Peptides, 2012, 177, 68-72.	1.9	12
148	Biophysical interaction between corticosteroids and natural surfactant preparation: implications for pulmonary drug delivery using surfactant as a carrier. Soft Matter, 2012, 8, 504-511.	2.7	30
149	Pulmonary Gene Delivery Using Polymeric Nonviral Vectors. Bioconjugate Chemistry, 2012, 23, 3-20.	3.6	63

#	ARTICLE	IF	CITATIONS
150	Deposition, Diffusion and Transport Mechanism of Dry Powder Microparticulate Salbutamol, at the Respiratory Epithelia. <i>Molecular Pharmaceutics</i> , 2012, 9, 1717-1726.	4.6	51
151	Strategies for non-invasive delivery of biologics. <i>Journal of Drug Targeting</i> , 2012, 20, 481-501.	4.4	48
152	Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16095-16100.	7.1	52
153	Pulmonary delivery and tissue distribution of aerosolized antisense 2'-O-Methyl RNA containing nanoplexes in the isolated perfused and ventilated rat lung. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 478-485.	4.3	18
154	Formulation technologies to overcome unfavorable properties of peptides and proteins for pulmonary delivery. <i>Drug Discovery Today: Technologies</i> , 2012, 9, e141-e146.	4.0	25
155	Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 82, 272-280.	4.3	53
156	Preparation of Nanoparticles by Spray-Drying and Their Use for Efficient Pulmonary Drug Delivery. , 2012, 906, 295-301.		5
157	Pulmonary Vaccine Delivery: A Realistic Approach?. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 249-260.	1.4	47
158	Nanoparticle-Mediated Treatment of Pulmonary Arterial Hypertension. <i>Methods in Enzymology</i> , 2012, 508, 325-354.	1.0	25
159	Controlled Release Pulmonary Administration of Curcumin Using Swellable Biocompatible Microparticles. <i>Molecular Pharmaceutics</i> , 2012, 9, 269-280.	4.6	112
160	Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. <i>Therapeutic Delivery</i> , 2012, 3, 735-747.	2.2	32
161	The Interplay of Lung Surfactant Proteins and Lipids Assimilates the Macrophage Clearance of Nanoparticles. <i>PLoS ONE</i> , 2012, 7, e40775.	2.5	123
162	Suppression of lung cancer progression by biocompatible glycerol triacrylate–spermine-mediated delivery of shAkt1. <i>International Journal of Nanomedicine</i> , 2012, 7, 2293.	6.7	21
163	LIPID NANOPARTICULATE DRUG DELIVERY AND NANOMEDICINE. , 2012, , 221-268.		4
164	Controlled release of 5-fluorouracil and progesterone from magnetic nanoaggregates. <i>International Journal of Nanomedicine</i> , 2012, 7, 3167.	6.7	9
165	Development of Budesonide Nanocluster Dry Powder Aerosols: Processing. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3425-3433.	3.3	11
166	One-Step Formulation of Protein Microparticles with Tailored Properties: Hard Templating at Soft Conditions. <i>Advanced Functional Materials</i> , 2012, 22, 1914-1922.	14.9	77
167	Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery. <i>Lung</i> , 2012, 190, 251-262.	3.3	119

#	ARTICLE	IF	CITATIONS
168	In Vitro and In Vivo Characterisation of PEG-Lipid-Based Micellar Complexes of Salmon Calcitonin for Pulmonary Delivery. <i>Pharmaceutical Research</i> , 2012, 29, 1425-1434.	3.5	28
169	Comparing MDI and DPI Aerosol Deposition Using In Vitro Experiments and a New Stochastic Individual Path (SIP) Model of the Conducting Airways. <i>Pharmaceutical Research</i> , 2012, 29, 1670-1688.	3.5	142
170	Lung imaging “Two dimensional gamma scintigraphy, SPECT, CT and PET. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 357-368.	13.7	51
171	Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics. <i>International Journal of Pharmaceutics</i> , 2012, 422, 428-435.	5.2	6
172	Aerosolized semifluorinated alkanes as excipients are suitable for inhalative drug delivery“A pilot study. <i>International Journal of Pharmaceutics</i> , 2012, 422, 194-201.	5.2	13
173	The development of a novel dry powder inhaler. <i>International Journal of Pharmaceutics</i> , 2012, 431, 45-52.	5.2	19
174	Conception, preparation and properties of functional carrier particles for pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2012, 433, 51-59.	5.2	38
175	Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer. <i>Biomaterials</i> , 2012, 33, 5574-5583.	11.4	153
176	Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. <i>Journal of Controlled Release</i> , 2012, 157, 149-159.	9.9	240
177	Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. <i>Journal of Controlled Release</i> , 2012, 157, 406-417.	9.9	34
178	Controlled pulmonary drug and gene delivery using polymeric nano-carriers. <i>Journal of Controlled Release</i> , 2012, 161, 214-224.	9.9	177
179	Towards tailored vaccine delivery: Needs, challenges and perspectives. <i>Journal of Controlled Release</i> , 2012, 161, 363-376.	9.9	93
180	Drug nanocrystals: In vivo performances. <i>Journal of Controlled Release</i> , 2012, 160, 418-430.	9.9	277
181	Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system. <i>Journal of Controlled Release</i> , 2012, 161, 728-734.	9.9	62
182	Nanocluster Budesonide Formulations Enhance Drug Delivery through Endotracheal Tubes. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 1063-1072.	3.3	12
183	Investigations into the Fate of Inhaled Salmon Calcitonin at the Respiratory Epithelial Barrier. <i>Pharmaceutical Research</i> , 2012, 29, 332-341.	3.5	12
184	Spherical agglomerates of pure drug nanoparticles for improved pulmonary delivery in dry powder inhalers. <i>Journal of Nanoparticle Research</i> , 2013, 15, 1.	1.9	12
185	Development and Characterization of Nanostructured Mists with Potential for Actively Targeting Poorly Water-Soluble Compounds into the Lungs. <i>Pharmaceutical Research</i> , 2013, 30, 2625-2639.	3.5	20

#	ARTICLE	IF	CITATIONS
186	Pulmonary Administration of PEGylated Polylysine Dendrimers: Absorption from the Lung versus Retention within the Lung Is Highly Size-Dependent. <i>Molecular Pharmaceutics</i> , 2013, 10, 2986-2995.	4.6	93
187	Mechanisms of absorption and elimination of drugs administered by inhalation. <i>Therapeutic Delivery</i> , 2013, 4, 1027-1045.	2.2	45
188	Pulmonary delivery of d-methionine is associated with an increase in ALCAR and glutathione in cochlear fluids. <i>Hearing Research</i> , 2013, 298, 93-103.	2.0	14
189	Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 699-711.	4.0	89
190	Synthesis and characterization of monodisperse uniformly shaped respirable aerosols. <i>AIChE Journal</i> , 2013, 59, 3184-3194.	3.6	11
191	Characterizing Systemic Exposure of Inhaled Drugs: Application to the Long-Acting β_2 -Agonist PF-00610355. <i>Clinical Pharmacokinetics</i> , 2013, 52, 443-452.	3.5	9
192	Devices for overcoming biological barriers: The use of physical forces to disrupt the barriers. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 100-103.	13.7	119
193	Seizure protection by intrapulmonary delivery of midazolam in mice. <i>Neuropharmacology</i> , 2013, 73, 425-431.	4.1	8
194	Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex. <i>International Journal of Pharmaceutics</i> , 2013, 440, 273-282.	5.2	58
195	In vivo lung deposition and sub-acute inhalation toxicity studies of nano-sized alendronate sodium as an antidote for inhaled toxic substances in Sprague Dawley rats. <i>Environmental Toxicology and Pharmacology</i> , 2013, 36, 636-647.	4.0	12
197	Aerosol generation using nanometer liposome suspensions for pulmonary drug delivery applications. <i>Journal of Liposome Research</i> , 2013, 23, 255-267.	3.3	22
198	Physicochemical Properties of Nanoparticles Regulate Translocation across Pulmonary Surfactant Monolayer and Formation of Lipoprotein Corona. <i>ACS Nano</i> , 2013, 7, 10525-10533.	14.6	181
199	Clinical translation of RNAi-based treatments for respiratory diseases. <i>Drug Delivery and Translational Research</i> , 2013, 3, 84-99.	5.8	6
200	Pocket-sized ultrasonic nebulizer for inhalation drug delivery. , 2013, , .		3
201	Linear theory on temporal instability of megahertz faraday waves for monodisperse microdroplet ejection. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2013, 60, 1746-1755.	3.0	11
202	Can Controversial Nanotechnology Promise Drug Delivery?. <i>Chemical Reviews</i> , 2013, 113, 1686-1735.	47.7	181
203	Oral drug delivery systems using chemical conjugates or physical complexes. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 845-864.	13.7	85
204	Following the Concentration of Polymeric Nanoparticles During Nebulization. <i>Pharmaceutical Research</i> , 2013, 30, 16-24.	3.5	26

#	ARTICLE	IF	CITATIONS
205	<i>In Silico</i> Physicochemical Parameter Predictions. <i>Molecular Pharmaceutics</i> , 2013, 10, 1224-1235.	4.6	42
207	Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. <i>Journal of Controlled Release</i> , 2013, 171, 234-240.	9.9	36
208	Expression and function of PEPT2 during transdifferentiation of alveolar epithelial cells. <i>Life Sciences</i> , 2013, 93, 630-636.	4.3	15
209	Bioactive insulin microparticles produced by supercritical fluid assisted atomization with an enhanced mixer. <i>International Journal of Pharmaceutics</i> , 2013, 454, 174-182.	5.2	19
210	Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery. <i>Powder Technology</i> , 2013, 239, 183-192.	4.2	30
211	Pulmonary dispersion formulations: The impact of dispersed powder properties on pressurized metered dose inhaler stability. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 413-424.	2.0	10
214	Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 604-613.	4.3	29
215	Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. <i>Biomaterials</i> , 2013, 34, 6444-6453.	11.4	115
216	Pulmonary drug delivery: from generating aerosols to overcoming biological barriers—therapeutic possibilities and technological challenges. <i>Lancet Respiratory Medicine</i> , 2013, 1, 402-413.	10.7	203
217	The development of models for the evaluation of pulmonary drug disposition. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 487-505.	3.3	15
218	Smart™ non-viral delivery systems for targeted delivery of RNAi to the lungs. <i>Therapeutic Delivery</i> , 2013, 4, 59-76.	2.2	12
219	How do polymeric micelles cross epithelial barriers?. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 42-55.	4.0	82
220	Supercritical fluid technology based large porous celecoxib PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. <i>Journal of Controlled Release</i> , 2013, 168, 239-250.	9.9	45
221	Inhaled biopharmaceutical drug development: nonclinical considerations and case studies. <i>Inhalation Toxicology</i> , 2013, 25, 219-232.	1.6	31
222	Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers. <i>International Journal of Pharmaceutics</i> , 2013, 441, 611-619.	5.2	33
223	Devices and formulations for pulmonary vaccination. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 1383-1397.	5.0	54
224	MicroRNA Expression in Cystic Fibrosis Airway Epithelium. <i>Biomolecules</i> , 2013, 3, 157-167.	4.0	5
225	Nicotine Delivery to Rats via Lung Alveolar Region-Targeted Aerosol Technology Produces Blood Pharmacokinetics Resembling Human Smoking. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1248-1258.	2.6	29

#	ARTICLE	IF	CITATIONS
226	Synthesis, characterization and <i>in vitro</i> extracellular and intracellular activity against <i>Mycobacterium tuberculosis</i> infection of new second-line antitubercular drug-palladium complexes. Journal of Pharmacy and Pharmacology, 2013, 66, 106-121.	2.4	19
227	Particle Transport and Deposition: Basic Physics of Particle Kinetics. , 2013, 3, 1437-1471.		192
228	Pulmonary pharmacokinetics of tulathromycin in swine. Part 2: Intra-airways compartments. Journal of Veterinary Pharmacology and Therapeutics, 2013, 36, 340-349.	1.3	18
229	Development, characterisation and pharmacoscintigraphic evaluation of nano-fluticasone propionate dry powder inhalation as potential antidote against inhaled toxic gases. Journal of Microencapsulation, 2013, 30, 546-558.	2.8	20
232	Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. International Journal of Nanomedicine, 2013, 8, 1269.	6.7	26
233	Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. International Journal of Nanomedicine, 2013, 8, 2975.	6.7	48
234	Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. International Journal of Nanomedicine, 2013, 8, 2975.	6.7	37
235	Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Design, Development and Therapy, 2013, 7, 59.	4.3	30
238	Faraday instability-based micro droplet ejection for inhalation drug delivery. Technology, 2014, 02, 75-81.	1.4	19
239	Early-Stage Development of Novel Cyclodextrin-siRNA Nanocomplexes Allows for Successful Postnebulization Transfection of Bronchial Epithelial Cells. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2014, 27, 466-477.	1.4	32
240	Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. Journal of Controlled Release, 2014, 196, 344-354.	9.9	96
241	Novel Formulations for Antimicrobial Peptides. International Journal of Molecular Sciences, 2014, 15, 18040-18083.	4.1	112
242	Engineered Aerosol Medicine and Drug Delivery Methods for Optimal Respiratory Therapy. Respiratory Care, 2014, 59, 1608-1610.	1.6	5
243	The Design of the Indacaterol Molecule. Milestones in Drug Therapy, 2014, , 39-65.	0.1	1
244	Gene expression analysis of membrane transporters and drug-metabolizing enzymes in the lung of healthy and COPD subjects. Pharmacology Research and Perspectives, 2014, 2, e00054.	2.4	23
245	Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 1076-1085.	4.3	30
246	Swellable Ciprofloxacin-Loaded Nano-in-Micro Hydrogel Particles for Local Lung Drug Delivery. AAPS PharmSciTech, 2014, 15, 1535-1544.	3.3	41
247	A novel aerosol generator for homogenous distribution of powder over the lungs after pulmonary administration to small laboratory animals. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 1056-1063.	4.3	32

#	ARTICLE	IF	CITATIONS
248	CARS microscopy as a tool for studying the distribution of micronised drugs in adhesive mixtures for inhalation. <i>Journal of Raman Spectroscopy</i> , 2014, 45, 495-500.	2.5	22
249	Targeted Lung Delivery of Nasally Administered Aerosols. <i>Aerosol Science and Technology</i> , 2014, 48, 434-449.	3.1	33
250	Understanding the Mutual Impact of Interaction between Hydrophobic Nanoparticles and Pulmonary Surfactant Monolayer. <i>Small</i> , 2014, 10, 1069-1075.	10.0	22
251	Encapsulation into PEG-Liposomes Does Not Improve the Bioavailability of Pulmonary Delivered Salmon Calcitonin. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2014, 27, 1-11.	1.4	28
252	Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics. <i>European Journal of Nanomedicine</i> , 2014, 6, .	0.6	42
253	Preparation of Nanoscale Pulmonary Drug Delivery Formulations by Spray Drying. <i>Advances in Experimental Medicine and Biology</i> , 2014, 811, 183-206.	1.6	18
254	The effects of engineered nanoparticles on pulmonary immune homeostasis. <i>Drug Metabolism Reviews</i> , 2014, 46, 176-190.	3.6	41
255	Measurement of the size and charge distribution of sodium chloride particles generated by an Aeroneb Pro [®] pharmaceutical nebulizer. <i>European Journal of Nanomedicine</i> , 2014, 6, .	0.6	7
256	Overcoming Dose Limitations Using the Orbital [®] Multi-Breath Dry Powder Inhaler. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2014, 27, 138-147.	1.4	42
257	Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 38-45.	4.3	19
258	Real-time in vivo imaging of surface-modified liposomes to evaluate their behavior after pulmonary administration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 115-119.	4.3	41
259	CaCO ₃ templated micro-beads and -capsules for bioapplications. <i>Advances in Colloid and Interface Science</i> , 2014, 207, 306-324.	14.7	140
260	Stability and cell uptake of calcium carbonate templated insulin microparticles. <i>Acta Biomaterialia</i> , 2014, 10, 1423-1430.	8.3	31
261	Controlling the droplet size of formulations nebulized by vibrating-membrane technology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 87, 524-529.	4.3	20
262	Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline. <i>Drug Delivery and Translational Research</i> , 2014, 4, 256-267.	5.8	7
263	Stimuli responsive nanocarrier for an effective delivery of multi-frontline tuberculosis drugs. <i>Polymer Chemistry</i> , 2014, 5, 2725-2735.	3.9	16
264	In Vitro Cell Integrated Impactor Deposition Methodology for the Study of Aerodynamically Relevant Size Fractions from Commercial Pressurised Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2014, 31, 1779-1787.	3.5	33
265	Formulation and evaluation of novel reverse microemulsions containing salmon calcitonin in hydrofluoroalkane propellants. <i>International Journal of Pharmaceutics</i> , 2014, 466, 390-399.	5.2	15

#	ARTICLE	IF	CITATIONS
266	An overview of clinical and commercial impact of drug delivery systems. <i>Journal of Controlled Release</i> , 2014, 190, 15-28.	9.9	379
267	Dry powders for oral inhalation free of lactose carrier particles. <i>Advanced Drug Delivery Reviews</i> , 2014, 75, 32-52.	13.7	172
268	Efficient Bioactive Delivery of Aerosolized Drugs to Human Pulmonary Epithelial Cells Cultured in Air–Liquid Interface Conditions. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 51, 526-535.	2.9	92
269	Advances in Inhaled Technologies: Understanding the Therapeutic Challenge, Predicting Clinical Performance, and Designing the Optimal Inhaled Product. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 509-520.	4.7	53
270	Pulmonary drug delivery by powder aerosols. <i>Journal of Controlled Release</i> , 2014, 193, 228-240.	9.9	151
271	Advances in Device and Formulation Technologies for Pulmonary Drug Delivery. <i>AAPS PharmSciTech</i> , 2014, 15, 882-897.	3.3	63
272	The impact of pulmonary diseases on the fate of inhaled medicines—A review. <i>International Journal of Pharmaceutics</i> , 2014, 461, 112-128.	5.2	46
274	Regulation of the Proteasome: Evaluating the Lung Proteasome as a New Therapeutic Target. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 2364-2382.	5.4	34
275	Administration strategies for proteins and peptides. <i>International Journal of Pharmaceutics</i> , 2014, 477, 578-589.	5.2	82
276	The Influence of Feedstock and Process Variables on the Encapsulation of Drug Suspensions by Spray–Drying in Fast Drying Regime: The Case of Novel Antitubercular Drug–Palladium Complex Containing Polymeric Microparticles. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1255-1268.	3.3	18
277	Increased Bioavailability of Rifampicin from Stimuli-Responsive Smart Nano Carrier. <i>ACS Applied Materials & Interfaces</i> , 2014, 6, 16895-16902.	8.0	21
278	Targeting Inhaled Therapy beyond the Lungs. <i>Respiration</i> , 2014, 88, 353-364.	2.6	29
279	The Cell Line NCI-H441 Is a Useful <i>in Vitro</i> Model for Transport Studies of Human Distal Lung Epithelial Barrier. <i>Molecular Pharmaceutics</i> , 2014, 11, 995-1006.	4.6	105
280	The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy. <i>Journal of Microencapsulation</i> , 2014, 31, 785-795.	2.8	42
281	Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery. <i>RSC Advances</i> , 2014, 4, 32673-32689.	3.6	85
282	Modeling Nanoparticle–Alveolar Epithelial Cell Interactions under Breathing Conditions Using Captive Bubble Surface Tension. <i>Langmuir</i> , 2014, 30, 4924-4932.	3.5	19
283	Combination of doxorubicin-based chemotherapy and polyethylenimine/p53 gene therapy for the treatment of lung cancer using porous PLGA microparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 122, 498-504.	5.0	43
284	A high-affinity peptide for nicotinic acetylcholine receptor- $\alpha 1$ and its potential use in pulmonary drug delivery. <i>Journal of Controlled Release</i> , 2014, 192, 141-147.	9.9	8

#	ARTICLE	IF	CITATIONS
285	In vitro evaluation of the DP-4M PennCenturyâ„¢ insufflator. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 153-159.	4.3	35
286	Polymeric Nanocarriers for Transport Modulation across the Pulmonary Epithelium: Dendrimers, Polymeric Nanoparticles, and their Nanoblends. AAPS Journal, 2014, 16, 522-538.	4.4	15
287	Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective. Journal of Veterinary Pharmacology and Therapeutics, 2014, 37, 211-221.	1.3	21
288	Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: A critical evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 23-30.	4.3	54
289	Targeting and in vivo imaging of non-smallâ€“cell lung cancer using nebulized multimodal contrast agents. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9247-9252.	7.1	52
290	Chemosensory Functions for Pulmonary Neuroendocrine Cells. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 637-646.	2.9	113
291	Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. British Journal of Pharmacology, 2014, 171, 3963-3979.	5.4	91
292	Capreomycin inhalable powders prepared with an innovative spray-drying technique. International Journal of Pharmaceutics, 2014, 469, 132-139.	5.2	31
293	Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. Journal of Controlled Release, 2014, 174, 15-26.	9.9	100
294	Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 386-394.	4.3	20
295	Sonocrystallization and sonofragmentation. Ultrasonics Sonochemistry, 2014, 21, 1908-1915.	8.2	179
296	Boosting the aerodynamic properties of vibrating-mesh nebulized polymeric nanosuspensions. International Journal of Pharmaceutics, 2014, 459, 23-29.	5.2	19
297	Discovery of AZD3199, An Inhaled Ultralong Acting β_2 Receptor Agonist with Rapid Onset of Action. ACS Medicinal Chemistry Letters, 2014, 5, 416-421.	2.8	23
298	siRNA Delivery to the lung: What's new?. Advanced Drug Delivery Reviews, 2014, 75, 112-128.	13.7	113
299	Enzyme-Responsive Hydrogel Microparticles for Pulmonary Drug Delivery. ACS Applied Materials & Interfaces, 2014, 6, 10313-10321.	8.0	86
300	Poly(amidoamine) Dendrimer Nanocarriers and Their Aerosol Formulations for siRNA Delivery to the Lung Epithelium. Molecular Pharmaceutics, 2014, 11, 1808-1822.	4.6	95
301	The role of respiratory flow asynchrony on convective mixing in the pulmonary acinus. Fluid Dynamics Research, 2014, 46, 041407.	1.3	16
302	Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 136-147.	4.3	39

#	ARTICLE	IF	CITATIONS
303	Core-shell nanocarriers for cancer therapy. Part I: biologically oriented design rules. Expert Opinion on Drug Delivery, 2014, 11, 283-297.	5.0	21
304	Enhancing therapeutic efficacy through designed aggregation of nanoparticles. Biomaterials, 2014, 35, 7860-7869.	11.4	40
306	Delivery strategies for sustained drug release in the lungs. Advanced Drug Delivery Reviews, 2014, 75, 81-91.	13.7	298
307	Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies. Advanced Drug Delivery Reviews, 2014, 75, 92-111.	13.7	101
308	Characterization of different vitamin E carriers intended for pulmonary drug delivery. International Journal of Pharmaceutics, 2014, 471, 385-390.	5.2	22
310	Fabrication of Solid Collagen Nanoparticles Using Electrospray Deposition. Chemical and Pharmaceutical Bulletin, 2014, 62, 422-428.	1.3	45
311	Nanotoxicity of Polymeric and Solid Lipid Nanoparticles. , 2014, , 160-177.		3
312	Developing accurate models of the human airways. Journal of Pharmacy and Pharmacology, 2015, 67, 464-472.	2.4	8
315	Particle dynamics and deposition in true-scale pulmonary acinar models. Scientific Reports, 2015, 5, 14071.	3.3	73
316	Ultrasound-driven Megahertz Faraday Waves for Generation of Monodisperse Micro Droplets and Applications. Physics Procedia, 2015, 70, 872-875.	1.2	4
317	Orotracheal administration of contrast agents: a new protocol for brain tumor targeting. NMR in Biomedicine, 2015, 28, 738-746.	2.8	14
319	Evaluation of nano spray drying as a method for drying and formulation of therapeutic peptides and proteins. Frontiers in Pharmacology, 2015, 6, 140.	3.5	62
321	Thein vitroandin vivo investigation of inhaled migraine therapies using a novel aerosol delivery system consisting of an air pressurized capsule device (APCD) in combination with a pMDI spacer for endotracheal dosing into beagle dogs. Drug Development and Industrial Pharmacy, 2015, 41, 1989-1996.	2.0	5
322	Pulmonary Administration of Subunit Vaccines. Advances in Delivery Science and Technology, 2015, , 307-329.	0.4	1
323	Cationic, amphiphilic dextran nanomicellar clusters as an excipient for dry powder inhaler formulation. Acta Biomaterialia, 2015, 23, 172-188.	8.3	14
324	Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery. Pharmaceutical Research, 2015, 32, 3248-3260.	3.5	36
325	Clinical Pharmacokinetics of Inhaled Antimicrobials. Clinical Pharmacokinetics, 2015, 54, 473-492.	3.5	20
326	Novel Delivery Systems for Improving the Clinical Use of Peptides. Pharmacological Reviews, 2015, 67, 541-561.	16.0	62

#	ARTICLE	IF	CITATIONS
327	The Application of Nanotechnology to Drug Delivery in Medicine. , 2015, , 173-223.		12
328	Formulation Design of Dry Powders for Inhalation. Journal of Pharmaceutical Sciences, 2015, 104, 3259-3288.	3.3	99
329	Roughness-controlled self-assembly of nanorod-covered mannitol/LB Agar microparticles by polymorphic transformation for pulmonary drug delivery. , 2015, , .		1
330	Revisiting pulmonary acinar particle transport: convection, sedimentation, diffusion, and their interplay. Journal of Applied Physiology, 2015, 118, 1375-1385.	2.5	55
331	The future perspectives of natural materials for pulmonary drug delivery and lung tissue engineering. Expert Opinion on Drug Delivery, 2015, 12, 869-887.	5.0	13
332	Newer devices and improved formulations of inhaled insulin. Expert Opinion on Drug Delivery, 2015, 12, 917-928.	5.0	13
333	Pulmonary Insulin-like Growth Factor I Delivery from Trehalose and Silk-Fibroin Microparticles. ACS Biomaterials Science and Engineering, 2015, 1, 119-129.	5.2	16
334	Roughness-Controlled Self-Assembly of Mannitol/LB Agar Microparticles by Polymorphic Transformation for Pulmonary Drug Delivery. Molecular Pharmaceutics, 2015, 12, 223-231.	4.6	8
335	Dendrimer Nanocarriers for Transport Modulation Across Models of the Pulmonary Epithelium. Molecular Pharmaceutics, 2015, 12, 826-838.	4.6	31
336	Formulation and characterization of inhalable magnetic nanocomposite microparticles (MnMs) for targeted pulmonary delivery via spray drying. International Journal of Pharmaceutics, 2015, 479, 320-328.	5.2	66
337	The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Advanced Drug Delivery Reviews, 2015, 91, 109-124.	13.7	177
338	Surface-active drug loaded lipopolymeric nanohybrid aerosol therapy: potential non-invasive way to mitigate lipopolysaccharide mediated inflammation in murine lungs. RSC Advances, 2015, 5, 9683-9694.	3.6	4
339	Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy. Advanced Drug Delivery Reviews, 2015, 85, 57-64.	13.7	20
340	Inhaled nano- and microparticles for drug delivery. Global Cardiology Science & Practice, 2015, 2015, 2.	0.4	144
341	Quantitative detection of drug dose and spatial distribution in the lung revealed by Cryoslicing Imaging. Journal of Pharmaceutical and Biomedical Analysis, 2015, 102, 129-136.	2.8	14
342	Chemical and Physicochemical Approaches to Solve Formulation Problems. , 2015, , 767-791.		5
343	Matrix metalloproteinase-sensitive hydrogel microparticles for pulmonary drug delivery of small molecule drugs or proteins. Journal of Materials Chemistry B, 2015, 3, 5629-5634.	5.8	27
344	Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections. Pharmaceutical Research, 2015, 32, 3850-3861.	3.5	15

#	ARTICLE	IF	CITATIONS
345	Customized Vibrating-Membrane Nozzles for Enhanced Fluid Atomization. <i>Aerosol Science and Technology</i> , 2015, 49, iii-viii.	3.1	6
346	Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs. <i>AAPS Journal</i> , 2015, 17, 853-870.	4.4	68
347	Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation. <i>AAPS PharmSciTech</i> , 2015, 16, 1299-1306.	3.3	14
348	Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data. <i>Pharmaceutical Research</i> , 2015, 32, 3170-3187.	3.5	93
349	Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. <i>Biomicrofluidics</i> , 2015, 9, 052603.	2.4	63
351	Porous PLGA microparticles to encapsulate doxorubicin and polyethylenimine/miR-34a for inhibiting the proliferation and migration of lung cancer. <i>RSC Advances</i> , 2015, 5, 81445-81448.	3.6	11
352	Inhalable liposomal dry powder of gemcitabine-HCl: Formulation, in vitro characterization and in vivo studies. <i>International Journal of Pharmaceutics</i> , 2015, 496, 886-895.	5.2	39
354	Characterisation of dry powder inhaler formulations using atomic force microscopy. <i>International Journal of Pharmaceutics</i> , 2015, 494, 393-407.	5.2	27
355	Generation of tailored aerosols for inhalative drug delivery employing recent vibrating-mesh nebulizer systems. <i>Therapeutic Delivery</i> , 2015, 6, 621-636.	2.2	18
356	The in vitro and in vivo investigation of a novel small chamber dry powder inhalation delivery system for preclinical dosing to rats. <i>Inhalation Toxicology</i> , 2015, 27, 706-716.	1.6	4
358	The advantages of pulmonary delivery of therapeutic siRNA. <i>Therapeutic Delivery</i> , 2015, 6, 407-409.	2.2	15
359	Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 89, 163-174.	4.3	114
360	Safety and Biocompatibility of Carbohydrate-Functionalized Polyanhydride Nanoparticles. <i>AAPS Journal</i> , 2015, 17, 256-267.	4.4	41
361	Protein stability in pulmonary drug delivery via nebulization. <i>Advanced Drug Delivery Reviews</i> , 2015, 93, 79-94.	13.7	81
362	The role of disposable inhalers in pulmonary drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 143-157.	5.0	21
363	Aerosol particle generation from solution-based pressurized metered dose inhalers: a technical overview of parameters that influence respiratory deposition. <i>Pharmaceutical Development and Technology</i> , 2015, 20, 897-910.	2.4	14
364	Deposition of particles in the alveolar airways: Inhalation and breath-hold with pharmaceutical aerosols. <i>Journal of Aerosol Science</i> , 2015, 79, 15-30.	3.8	72
365	Drug delivery and nanodetection in lung cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 618-634.	2.8	21

#	ARTICLE	IF	CITATIONS
366	Surfactant-based drug delivery systems for treating drug-resistant lung cancer. <i>Drug Delivery</i> , 2016, 23, 717-728.	5.7	63
367	Augmenting regional and targeted delivery in the pulmonary acinus using magnetic particles. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 3385-3395.	6.7	21
368	Tissue-based in vitro and ex vivo models for pulmonary permeability studies. , 2016, , 255-272.		1
369	Airway Epithelial Cell Cilia and Obstructive Lung Disease. <i>Cells</i> , 2016, 5, 40.	4.1	119
370	Delivery of RNAi Therapeutics to the Airways – From Bench to Bedside. <i>Molecules</i> , 2016, 21, 1249.	3.8	54
371	Nanotechnological applications for the control of pulmonary infections. , 2016, , 223-235.		2
372	Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds. <i>Frontiers in Pharmacology</i> , 2016, 7, 181.	3.5	154
373	Cell-based in vitro models for pulmonary permeability studies. , 2016, , 101-113.		3
374	Autologous Co-culture of Primary Human Alveolar Macrophages and Epithelial Cells for Investigating Aerosol Medicines. Part I: Model Characterisation. <i>ATLA Alternatives To Laboratory Animals</i> , 2016, 44, 337-347.	1.0	17
375	Autologous Co-culture of Primary Human Alveolar Macrophages and Epithelial Cells for Investigating Aerosol Medicines. Part II: Evaluation of IL-10-loaded Microparticles for the Treatment of Lung Inflammation. <i>ATLA Alternatives To Laboratory Animals</i> , 2016, 44, 349-360.	1.0	13
376	Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model. <i>Pharmaceutical Research</i> , 2016, 33, 2604-2616.	3.5	29
377	Protective effect of magnolol-loaded polyketal microparticles on lipopolysaccharide-induced acute lung injury in rats. <i>Journal of Microencapsulation</i> , 2016, 33, 401-411.	2.8	10
378	Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2016, 8, 842-871.	6.1	84
379	Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?. <i>Advances in Therapy</i> , 2016, 33, 1267-1278.	2.9	14
381	Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 538-552.	2.4	30
382	Evaluation of Proinflammatory Cytokines and Adverse Events in Healthy Volunteers upon Inhalation of Antituberculosis Drugs. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 1815-1822.	1.4	16
383	Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery. <i>Scientific Reports</i> , 2016, 6, 31732.	3.3	36
384	Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 1-39.	0.6	4

#	ARTICLE	IF	CITATIONS
387	Formulation of insulin-loaded N -trimethyl chitosan microparticles with improved efficacy for inhalation by supercritical fluid assisted atomization. International Journal of Pharmaceutics, 2016, 505, 223-233.	5.2	31
388	Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. Journal of Controlled Release, 2016, 230, 45-56.	9.9	24
389	A dry powder combination of pyrazinoic acid and its n -propyl ester for aerosol administration to animals. International Journal of Pharmaceutics, 2016, 514, 384-391.	5.2	14
390	Inhaled Antibiotics for Gram-Negative Respiratory Infections. Clinical Microbiology Reviews, 2016, 29, 581-632.	13.6	97
391	Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation. Pharmaceutical Research, 2016, 33, 2107-2116.	3.5	9
392	The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis. International Journal of Pharmaceutics, 2016, 514, 392-398.	5.2	19
393	Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution. Molecular Pharmaceutics, 2016, 13, 1866-1878.	4.6	52
394	Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation. Molecular Pharmaceutics, 2016, 13, 1904-1914.	4.6	30
395	Diesel exhaust: current knowledge of adverse effects and underlying cellular mechanisms. Archives of Toxicology, 2016, 90, 1541-1553.	4.2	213
396	Improving the Intracellular Drug Concentration in Lung Cancer Treatment through the Codelivery of Doxorubicin and miR-519c Mediated by Porous PLGA Microparticle. Molecular Pharmaceutics, 2016, 13, 3925-3933.	4.6	39
397	Fluorescence lifetime imaging of optically levitated aerosol: a technique to quantitatively map the viscosity of suspended aerosol particles. Physical Chemistry Chemical Physics, 2016, 18, 21710-21719.	2.8	30
398	Design of spray dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung dose. International Journal of Pharmaceutics, 2016, 511, 1070-1079.	5.2	16
399	Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 201-210.	2.5	53
400	Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension. International Journal of Pharmaceutics, 2016, 512, 305-313.	5.2	26
401	RTG-loaded nanomicelles (CSâ€“VESâ€“NAC) for oral anti-HIV drug delivery. RSC Advances, 2016, 6, 75890-75895.	3.6	4
402	Current <i>in vitro</i> approaches to assess nanoparticle interactions with lung cells. Nanomedicine, 2016, 11, 2457-2469.	3.3	31
403	The role of microRNAs in respiratory viral infection: friend or foe?. Reviews in Medical Virology, 2016, 26, 389-407.	8.3	40
404	Materials and methods for delivery of biological drugs. Nature Chemistry, 2016, 8, 997-1007.	13.6	245

#	ARTICLE	IF	CITATIONS
405	Drug Delivery Devices for Inhaled Medicines. Handbook of Experimental Pharmacology, 2016, 237, 265-280.	1.8	13
406	Pharmaceutical Applications of Electrospraying. Journal of Pharmaceutical Sciences, 2016, 105, 2601-2620.	3.3	139
407	The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery. International Journal of Pharmaceutics, 2016, 514, 465-474.	5.2	23
408	Influence of physical properties of carrier on the performance of dry powder inhalers. Acta Pharmaceutica Sinica B, 2016, 6, 308-318.	12.0	116
409	Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 461-481.	1.4	65
410	Oral uptake of nanoparticles: human relevance and the role of in vitro systems. Archives of Toxicology, 2016, 90, 2297-2314.	4.2	67
411	Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model. Pulmonary Pharmacology and Therapeutics, 2016, 36, 53-61.	2.6	37
412	Biphasic release of gentamicin from chitosan/fucoidan nanoparticles for pulmonary delivery. Carbohydrate Polymers, 2016, 138, 114-122.	10.2	90
413	A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep. Pharmaceutical Research, 2016, 33, 510-525.	3.5	22
414	Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1703-1724.	3.3	67
415	Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling. Pharmaceutical Research, 2016, 33, 1447-1455.	3.5	9
416	The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats. Journal of Pharmaceutical Sciences, 2016, 105, 293-300.	3.3	17
417	Effect of Inhaled Interferon Beta-1a on Carbon Monoxide Transfer Factor in Healthy Volunteers. Journal of Interferon and Cytokine Research, 2016, 36, 113-119.	1.2	0
418	Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases. Journal of Pharmaceutical Sciences, 2016, 105, 650-656.	3.3	27
419	Influence of amine-modified poly(vinyl alcohol)s on vibrating-membrane nebulizer performance and lung toxicity. European Journal of Pharmaceutical Sciences, 2016, 86, 34-40.	4.0	6
420	Functional and cytometric examination of different human lung epithelial cell types as drug transport barriers. Archives of Pharmacal Research, 2016, 39, 359-369.	6.3	11
421	Amorphous Calcium Carbonate Based-Microparticles for Peptide Pulmonary Delivery. ACS Applied Materials & Interfaces, 2016, 8, 1164-1175.	8.0	47
422	Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Delivery, 2016, 23, 2881-2896.	5.7	36

#	ARTICLE	IF	CITATIONS
423	Inhalable nanocomposite microparticles: preparation, characterization and factors affecting formulation. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 207-222.	5.0	17
424	Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 148-156.	2.2	48
425	Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization. <i>Journal of Controlled Release</i> , 2017, 249, 11-22.	9.9	65
426	Cellular internalization and transport of biodegradable polyester dendrimers on a model of the pulmonary epithelium and their formulation in pressurized metered-dose inhalers. <i>International Journal of Pharmaceutics</i> , 2017, 520, 181-194.	5.2	22
427	Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern. <i>Nanomedicine</i> , 2017, 12, 357-385.	3.3	119
428	Interaction of biomedical nanoparticles with the pulmonary immune system. <i>Journal of Nanobiotechnology</i> , 2017, 15, 6.	9.1	45
429	Physical principles of graphene cellular interactions: computational and theoretical accounts. <i>Journal of Materials Chemistry B</i> , 2017, 5, 4290-4306.	5.8	25
430	Pulmonary Delivery of Magnetically Targeted Nano-in-Microparticles. <i>Methods in Molecular Biology</i> , 2017, 1530, 369-378.	0.9	3
431	Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes. <i>AAPS Journal</i> , 2017, 19, 652-668.	4.4	109
432	ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. <i>Journal of Controlled Release</i> , 2017, 249, 103-110.	9.9	110
433	Enhancing the therapeutic potential of peptide toxins. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 611-623.	5.0	41
434	Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2234-2244.	3.3	22
435	Investigation of nanocarriers and excipients for preparation of nanoembedded microparticles. <i>International Journal of Pharmaceutics</i> , 2017, 526, 300-308.	5.2	11
436	Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 782-797.	6.1	196
437	The application of polysaccharide-based nanogels in peptides/proteins and anticancer drugs delivery. <i>Journal of Drug Targeting</i> , 2017, 25, 673-684.	4.4	23
438	The effect of non-specific tight junction modulators on the transepithelial transport of poorly permeable drugs across airway epithelial cells. <i>Journal of Drug Targeting</i> , 2017, 25, 342-349.	4.4	7
439	Endocytic Uptake, Transport and Macromolecular Interactions of Anionic PAMAM Dendrimers within Lung Tissue. <i>Pharmaceutical Research</i> , 2017, 34, 2517-2531.	3.5	20
440	TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations. <i>International Journal of Pharmaceutics</i> , 2017, 527, 171-183.	5.2	54

#	ARTICLE	IF	CITATIONS
441	Transport of nanoparticles across pulmonary surfactant monolayer: a molecular dynamics study. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 17568-17576.	2.8	32
442	Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening. <i>Drug Delivery</i> , 2017, 24, 891-905.	5.7	26
443	Dissolv<i>It</i>: An <i>In Vitro</i> Method for Simulating the Dissolution and Absorption of Inhaled Dry Powder Drugs in the Lungs. <i>Assay and Drug Development Technologies</i> , 2017, 15, 77-88.	1.2	38
444	Nanocrystals embedded in chitosan-based respirable swellable microparticles as dry powder for sustained pulmonary drug delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 99, 137-146.	4.0	63
445	Numerical modeling of particle deposition in ferret airways: A comparison with humans. <i>Aerosol Science and Technology</i> , 2017, 51, 477-487.	3.1	12
446	Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 151, 206-214.	5.0	27
447	The long and winding road to inhaled TB therapy: not only the bug's fault. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 347-363.	2.0	15
448	Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 767-786.	6.4	45
449	Aerosol Delivery of Functionalized Gold Nanoparticles Target and Activate Dendritic Cells in a 3D Lung Cellular Model. <i>ACS Nano</i> , 2017, 11, 375-383.	14.6	55
450	<i>In Vivo</i> Pulmonary Delivery and Magnetic-Targeting of Dry Powder Nano-in-Microparticles. <i>Molecular Pharmaceutics</i> , 2017, 14, 4741-4750.	4.6	48
452	Orotracheal manganese-enhanced MRI (MEMRI): An effective approach for lung tumor detection. <i>NMR in Biomedicine</i> , 2017, 30, e3790.	2.8	6
453	A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2017, 532, 537-546.	5.2	50
454	Metabolic effects of inhaled salbutamol determined by exhaled breath analysis. <i>Journal of Breath Research</i> , 2017, 11, 046004.	3.0	28
455	Effect of the pulmonary deposition and in vitro permeability on the prediction of plasma levels of inhaled budesonide formulation. <i>International Journal of Pharmaceutics</i> , 2017, 532, 337-344.	5.2	19
456	Inhalation delivery of complex drugs – the next steps. <i>Current Opinion in Pharmacology</i> , 2017, 36, 52-57.	3.5	36
457	Good Things in Small Packages: an Innovative Delivery Approach for Inhaled Insulin. <i>Pharmaceutical Research</i> , 2017, 34, 2568-2578.	3.5	19
458	Drug targeting to myofibroblasts: Implications for fibrosis and cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 121, 101-116.	13.7	121
459	Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 119, 408-418.	4.3	28

#	ARTICLE	IF	CITATIONS
460	Innovative pMDI formulations of spray-dried nanoparticles for efficient pulmonary drug delivery. International Journal of Pharmaceutics, 2017, 530, 12-20.	5.2	11
461	Enhanced pulmonary bioavailability of curcumin by some common excipients and relative therapeutic effects on sepsis-induced acute lung injury in rats. Journal of Drug Delivery Science and Technology, 2017, 41, 231-238.	3.0	2
462	The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers. European Journal of Pharmaceutical Sciences, 2017, 109, 86-95.	4.0	20
463	Pharmacokinetics and Bioavailability of Inhaled Esketamine in Healthy Volunteers. Anesthesiology, 2017, 127, 675-683.	2.5	32
464	PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals. Current Opinion in Colloid and Interface Science, 2017, 31, 43-50.	7.4	28
465	Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication. International Journal of Pharmaceutics, 2017, 531, 14-23.	5.2	8
466	Optimization of Acetalated Dextran-Based Nanocomposite Microparticles for Deep Lung Delivery of Therapeutics via Spray-Drying. Journal of Pharmaceutical Sciences, 2017, 106, 3539-3547.	3.3	18
467	Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines. Pharmaceutical Research, 2017, 34, 2451-2453.	3.5	12
468	Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals. Drug Delivery and Translational Research, 2017, 7, 558-570.	5.8	18
469	Biokinetics of Aerosolized Liposomal Ciclosporin A in Human Lung Cells In Vitro Using an Air-Liquid Cell Interface Exposure System. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 411-424.	1.4	18
470	Inhaled Antibiotics for Hospital-Acquired and Ventilator-Associated Pneumonia. Clinical Infectious Diseases, 2017, 64, 386-387.	5.8	13
471	The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers. Pharmaceutical Research, 2017, 34, 507-528.	3.5	77
472	Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery. Carbohydrate Polymers, 2017, 157, 991-1012.	10.2	53
473	A new fluorescence-based method for characterizing in vitro aerosol exposure systems. Toxicology in Vitro, 2017, 38, 150-158.	2.4	14
474	Safety, regulatory issues, long-term biotoxicity, and the processing environment. , 2017, , 261-279.		9
475	Therapeutic nanostructures for pulmonary drug delivery. , 2017, , 619-638.		16
476	Faraday Waves-Based Integrated Ultrasonic Micro-Droplet Generator and Applications. Micromachines, 2017, 8, 56.	2.9	12
477	Rationale for Pulmonary Vaccine Delivery: Formulation and Device Considerations. , 2017, , 357-371.		4

#	ARTICLE	IF	CITATIONS
478	Pulmonary Administration of Biodegradable Drug Nanocarriers for More Efficacious Treatment of Fungal Infections in Lungs: Insights Based on Recent Findings. , 2017, , 261-280.		0
479	On the Development of Focused Ultrasound Liquid Atomizers. Advances in Acoustics and Vibration, 2017, 2017, 1-10.	0.5	16
480	3.15 Cell Culture Systems for Studying Biomaterial Interactions With Biological Barriers â††. , 2017, , 295-334.		0
481	Performance evaluation of nebulizers based on aerodynamic droplet diameter characterization using the Direct Laminar Incidence (DLI). Research on Biomedical Engineering, 2017, 33, 105-112.	2.2	6
482	Polymerâ€™Lipid Microparticles for Pulmonary Delivery. Langmuir, 2018, 34, 3438-3448.	3.5	12
483	Antimicrobial molecules in the lung: formulation challenges and future directions for innovation. Future Medicinal Chemistry, 2018, 10, 575-604.	2.3	14
484	Immunoglobulin G particles manufacturing by spray drying process for pressurised metered dose inhaler formulations. Annales Pharmaceutiques Francaises, 2018, 76, 291-298.	1.0	5
485	Enantioselective resolution of <i>Rac</i>â€™terbutaline and evaluation of optically pure <i>R</i>â€™terbutaline hydrochloride as an efficient antiâ€™sthmatic drug. Chirality, 2018, 30, 759-768.	2.6	11
486	Cyclosporine A/porous quaternized chitosan microspheres as a novel pulmonary drug delivery system. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 552-564.	2.8	18
487	Influence of Formulation Factors on the Aerosol Performance and Stability of Lysozyme Powders: a Systematic Approach. AAPS PharmSciTech, 2018, 19, 2755-2766.	3.3	21
488	Intrapulmonary Milrinone for Cardiac Surgery Provides Insight Into Precision Delivery of Aerosolized Vasodilators. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 2139-2141.	1.3	1
489	Development and optimization of ciprofloxacin-loaded gelatin microparticles by single-step spray-drying technique. Powder Technology, 2018, 330, 201-209.	4.2	9
490	Organ-based drug delivery. Journal of Drug Targeting, 2018, 26, 385-397.	4.4	25
491	A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 125, 1-12.	4.3	42
492	Sonocrystallization of poly(3-hexylthiophene) in a marginal solvent. Soft Matter, 2018, 14, 3590-3600.	2.7	12
493	Repurposing rosiglitazone, a PPAR-Î³ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH. Journal of Controlled Release, 2018, 280, 113-123.	9.9	19
494	Pharmacokinetics and Pharmacodynamics of Nebulized and Intratracheal Milrinone in a Swine Model of Hypercapnia Pulmonary Hypertension. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 2130-2138.	1.3	6
495	Respiratory sensitization: toxicological point of view on the available assays. Archives of Toxicology, 2018, 92, 803-822.	4.2	31

#	ARTICLE	IF	CITATIONS
496	Enhanced uptake in 2D- and 3D- lung cancer cell models of redox responsive PEGylated nanoparticles with sensitivity to reducing extra- and intracellular environments. Journal of Controlled Release, 2018, 277, 126-141.	9.9	54
497	The Evaluation of BMAA Inhalation as a Potential Exposure Route Using a rat Model. Neurotoxicity Research, 2018, 33, 6-14.	2.7	16
498	Effect of the surface charge density of nanoparticles on their translocation across pulmonary surfactant monolayer: a molecular dynamics simulation. Molecular Simulation, 2018, 44, 85-93.	2.0	19
499	The role of mucus on drug transport and its potential to affect therapeutic outcomes. Advanced Drug Delivery Reviews, 2018, 124, 82-97.	13.7	218
500	One (sub-)acinus for all: Fate of inhaled aerosols in heterogeneous pulmonary acinar structures. European Journal of Pharmaceutical Sciences, 2018, 113, 53-63.	4.0	36
501	Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respiratory Medicine, 2018, 134, 16-23.	2.9	26
502	Comparison of plasma pharmacokinetics of Tanreqing solution between intratracheal aerosolization and intravenous injection in rats. Biomedical Chromatography, 2018, 32, e4116.	1.7	15
503	Ein Instrumentarium von Î±vâ€œRGDâ€œIntegrinâ€œInhibitoren: Wirkstoffsuche, Herausforderungen und MÃ¶glichkeiten. Angewandte Chemie, 2018, 130, 3354-3379.	2.0	12
504	Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products. European Journal of Pharmaceutical Sciences, 2018, 113, 18-28.	4.0	46
505	Particle deposition in tracheobronchial airways of an infant, child and adult. Science of the Total Environment, 2018, 612, 339-346.	8.0	80
506	Co-Spray Dried Mannitol/Poly(amidoamine)-Doxorubicin Dry-Powder Inhaler Formulations for Lung Adenocarcinoma: Morphology, In Vitro Evaluation, and Aerodynamic Performance. AAPS PharmSciTech, 2018, 19, 531-540.	3.3	21
507	The role of the solid state and physical properties of the carrier in adhesive mixtures for lung delivery. Expert Opinion on Drug Delivery, 2018, 15, 665-674.	5.0	14
508	Nanomaterials in the Prevention, Diagnosis, and Treatment of <i>Mycobacterium Tuberculosis</i> Infections. Advanced Healthcare Materials, 2018, 7, 1700509.	7.6	31
509	An Î±vâ€œRGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities. Angewandte Chemie - International Edition, 2018, 57, 3298-3321.	13.8	94
510	Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. Journal of Controlled Release, 2018, 269, 374-392.	9.9	263
511	Pulmonary drug delivery to older people. Advanced Drug Delivery Reviews, 2018, 135, 50-61.	13.7	19
512	Pulmonary absorption â€œ estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 124, 1-12.	4.3	31
513	The role of mucus as an invisible cloak to transepithelial drug delivery by nanoparticles. Advanced Drug Delivery Reviews, 2018, 124, 107-124.	13.7	85

#	ARTICLE	IF	CITATIONS
514	Process optimization and particle engineering of micronized drug powders via milling. Drug Delivery and Translational Research, 2018, 8, 1740-1750.	5.8	22
515	Nanotoxicity of Lipid-Based Nanomedicines. , 2018, , 133-165.		1
516	A lung/liver-on-a-chip platform for acute and chronic toxicity studies. Lab on A Chip, 2018, 18, 3814-3829.	6.0	132
517	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. Intensive Care Medicine Experimental, 2018, 6, 17.	1.9	7
518	Protease activity sensors noninvasively classify bacterial infections and antibiotic responses. EBioMedicine, 2018, 38, 248-256.	6.1	22
519	Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma. Science Translational Medicine, 2018, 10, .	12.4	24
520	Models of deposition, pharmacokinetics, and intersubject variability in respiratory drug delivery. Expert Opinion on Drug Delivery, 2018, 15, 1175-1188.	5.0	16
521	Inhaled nanomaterials and the respiratory microbiome: clinical, immunological and toxicological perspectives. Particle and Fibre Toxicology, 2018, 15, 46.	6.2	84
522	Antibiotic-nanomedicines: facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections. Future Microbiology, 2018, 13, 1683-1692.	2.0	13
523	Characterization of matrix embedded formulations for combination spray-dried particles comprising pyrazinamide and rifampicin. Journal of Drug Delivery Science and Technology, 2018, 48, 137-144.	3.0	16
524	Inhalation Toxicology Studies. , 2018, , 294-314.		2
525	Chronic intermittent nicotine delivery via lung alveolar region-targeted aerosol technology produces circadian pharmacokinetics in rats resembling human smokers. Journal of Applied Physiology, 2018, 125, 1555-1562.	2.5	7
526	Nanoemulsions in drug delivery: formulation to medical application. Nanomedicine, 2018, 13, 2507-2525.	3.3	109
527	Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculations. Regulatory Toxicology and Pharmacology, 2018, 100, 35-44.	2.7	10
528	Supercritical Fluid-Assisted Decoration of Nanoparticles on Porous Microcontainers for Codelivery of Therapeutics and Inhalation Therapy of Diabetes. ACS Biomaterials Science and Engineering, 2018, 4, 4225-4235.	5.2	29
529	Carbon nanodots: Opportunities and limitations to study their biodistribution at the human lung epithelial tissue barrier. Biointerphases, 2018, 13, 06D404.	1.6	7
530	Nanopharmaceuticals. , 2018, , 165-201.		1
531	Silica Nanoparticle-Induced Structural Reorganizations in Pulmonary Surfactant Films: What Monolayer Compression Isotherms Do Not Say. ACS Applied Nano Materials, 2018, 1, 5268-5278.	5.0	67

#	ARTICLE	IF	CITATIONS
532	Particle Disposition in the Realistic Airway Tree Models of Subjects with Tracheal Bronchus and COPD. BioMed Research International, 2018, 2018, 1-15.	1.9	8
533	Development of ciprofloxacin-loaded poly(vinyl alcohol) dry powder formulations for lung delivery. International Journal of Pharmaceutics, 2018, 547, 114-121.	5.2	13
534	Formulation techniques for high dose dry powders. International Journal of Pharmaceutics, 2018, 547, 489-498.	5.2	46
535	Maximising success in multidrug formulation development: A review. Journal of Controlled Release, 2018, 283, 1-19.	9.9	28
536	Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug Delivery, 2018, 25, 1127-1136.	5.7	14
537	Biomimetics of the pulmonary environment <i>in vitro</i>: A microfluidics perspective. Biomicrofluidics, 2018, 12, 042209.	2.4	43
538	Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice. Journal of Diabetes Research, 2018, 2018, 1-9.	2.3	26
539	Development and Characterization of Dapsone Cocrystal Prepared by Scalable Production Methods. AAPS PharmSciTech, 2018, 19, 2687-2699.	3.3	27
540	DPI formulations for high dose applications – Challenges and opportunities. International Journal of Pharmaceutics, 2018, 548, 49-53.	5.2	35
541	Pathway-based predictive approaches for non-animal assessment of acute inhalation toxicity. Toxicology in Vitro, 2018, 52, 131-145.	2.4	66
542	Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease. Frontiers in Pharmacology, 2018, 9, 759.	3.5	10
543	Use of Submicron Vaterite Particles Serves as an Effective Delivery Vehicle to the Respiratory Portion of the Lung. Frontiers in Pharmacology, 2018, 9, 559.	3.5	28
544	First-Pass Metabolism Considerations in Pharmaceutical Product Development. , 2018, , 259-286.		0
545	Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model. Frontiers in Microbiology, 2018, 9, 741.	3.5	12
546	An Inhalable Powder Formulation Based on Micro- and Nanoparticles Containing 5-Fluorouracil for the Treatment of Metastatic Melanoma. Nanomaterials, 2018, 8, 75.	4.1	19
547	Delivery of Therapeutics to the Lung. Methods in Molecular Biology, 2018, 1809, 415-429.	0.9	2
548	Role of Lipid Coating in the Transport of Nanodroplets across the Pulmonary Surfactant Layer Revealed by Molecular Dynamics Simulations. Langmuir, 2018, 34, 9054-9063.	3.5	24
549	Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes. Canadian Respiratory Journal, 2018, 2018, 1-11.	1.6	174

#	ARTICLE	IF	CITATIONS
550	Investigating the bioavailability of graphene quantum dots in lung tissues via Fourier transform infrared spectroscopy. <i>Interface Focus</i> , 2018, 8, 20170054.	3.0	26
551	A Partial Differential Equation Approach to Inhalation Physiologically Based Pharmacokinetic Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 638-646.	2.5	9
552	Inhalers and nebulizers: basic principles and preliminary measurements. <i>EPJ Web of Conferences</i> , 2018, 180, 02068.	0.3	2
553	Preclinical evaluation of aerosol administration systems using Positron Emission Tomography. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 130, 59-65.	4.3	13
554	Pulmonary administration of curcumin inhibits B16F10 melanoma lung metastasis and invasion in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 265-273.	2.3	15
555	Distribution of polymer-coated gold nanoparticles in a 3D lung model and indication of apoptosis after repeated exposure. <i>Nanomedicine</i> , 2018, 13, 1169-1185.	3.3	11
556	Enhancing Stability of Exenatide-Containing Pressurized Metered-Dose Inhaler Via Reverse Microemulsion System. <i>AAPS PharmSciTech</i> , 2018, 19, 2499-2508.	3.3	6
557	Advances in Biomaterials for Drug Delivery. <i>Advanced Materials</i> , 2018, 30, e1705328.	21.0	565
558	Sterile dosage forms loaded nanosystems for parenteral, nasal, pulmonary and ocular administration. , 2018, , 335-395.		2
559	Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing. <i>KONA Powder and Particle Journal</i> , 2019, 36, 129-144.	1.7	27
560	RNAi therapeutic strategies for acute respiratory distress syndrome. <i>Translational Research</i> , 2019, 214, 30-49.	5.0	15
561	Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 143, 61-69.	4.3	41
562	Targeting inhaled fibers to the pulmonary acinus: Opportunities for augmented delivery from in silico simulations. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 137, 105003.	4.0	17
563	In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. <i>Drug Delivery</i> , 2019, 26, 689-699.	5.7	16
564	Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2019, 32, 317-339.	1.4	31
565	Thermosensitive polysaccharide particles for pulmonary drug delivery. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2019, 580, 123720.	4.7	6
566	A mouse model for chronic intermittent electronic cigarette exposure exhibits nicotine pharmacokinetics resembling human vapers. <i>Journal of Neuroscience Methods</i> , 2019, 326, 108376.	2.5	29
567	Mucopenetrating lipoplexes modified with PEG and hyaluronic acid for CD44-targeted local siRNA delivery to the lungs. <i>Journal of Biomaterials Applications</i> , 2019, 34, 617-630.	2.4	24

#	ARTICLE	IF	CITATIONS
568	Analysis of indoor particles and gases and their evolution with natural ventilation. <i>Indoor Air</i> , 2019, 29, 761-779.	4.3	24
569	Nanoparticle-Based Drug Delivery for Chronic Obstructive Pulmonary Disorder and Asthma. , 2019, , 59-73.		10
570	Multiscale in silico lung modeling strategies for aerosol inhalation therapy and drug delivery. <i>Current Opinion in Biomedical Engineering</i> , 2019, 11, 130-136.	3.4	23
571	Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126658.	2.2	21
572	The Lord of the Lungs: The essential role of pulmonary surfactant upon inhalation of nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 144, 230-243.	4.3	78
573	Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus. <i>Journal of Immunology</i> , 2019, 202, 1595-1611.	0.8	7
574	Fluorescent reconstitution on deposition of PM _{2.5} in lung and extrapulmonary organs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2488-2493.	7.1	105
575	In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus. <i>International Journal of Pharmaceutics</i> , 2019, 559, 235-244.	5.2	20
576	Lipid Uptake by Alveolar Macrophages Drives Fibrotic Responses to Silica Dust. <i>Scientific Reports</i> , 2019, 9, 399.	3.3	39
577	Transcriptomic response of primary human airway epithelial cells to flavoring chemicals in electronic cigarettes. <i>Scientific Reports</i> , 2019, 9, 1400.	3.3	84
578	Facile Surface Multi-Functionalization of Biomedical Catheters with Dual-Microcrystalline Broad-Spectrum Antibacterial Drugs and Antifouling Poly(ethylene glycol) for Effective Inhibition of Bacterial Infections. <i>ACS Applied Bio Materials</i> , 2019, 2, 1348-1356.	4.6	29
579	Differential effects of inhaled R- and S-terbutaline in ovalbumin-induced asthmatic mice. <i>International Immunopharmacology</i> , 2019, 73, 581-589.	3.8	6
580	Behavioural effects of inhalation exposure to dizocilpine (MK-801) in mice. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109038.	5.6	7
581	Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats. <i>Journal of Controlled Release</i> , 2019, 307, 32-43.	9.9	26
582	Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model. <i>Molecular Pharmaceutics</i> , 2019, 16, 3053-3064.	4.6	23
583	Delivery of natural phenolic compounds for the potential treatment of lung cancer. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2019, 27, 433-449.	2.0	32
584	Microfluidic droplet liquid reactors for active pharmaceutical ingredient crystallization by diffusion controlled solvent extraction. <i>Lab on A Chip</i> , 2019, 19, 2127-2137.	6.0	23
585	Novel methods for the assessment of safety pharmacology and toxicology parameters in anesthetized and ventilated dogs receiving inhaled drugs. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019, 99, 106578.	0.7	3

#	ARTICLE	IF	CITATIONS
586	Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and data. <i>Critical Reviews in Toxicology</i> , 2019, 49, 160-173.	3.9	13
587	Targeted drug delivery and gene therapy through natural biodegradable nanostructures in pharmaceuticals. , 2019, , 437-472.		6
588	Biological Responses to Nanoscale Particles. <i>Nanoscience and Technology</i> , 2019, , .	1.5	9
589	Cellular and Non-cellular Barriers to Particle Transport Across the Lungs. <i>Nanoscience and Technology</i> , 2019, , 171-189.	1.5	0
590	Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery. <i>Journal of Pharmaceutical Investigation</i> , 2019, 49, 427-442.	5.3	74
591	CFD modelling of air and particle flows in different airway models. <i>Journal of Aerosol Science</i> , 2019, 134, 14-28.	3.8	33
592	Qualitative and quantitative analysis of the biophysical interaction of inhaled nanoparticles with pulmonary surfactant by using quartz crystal microbalance with dissipation monitoring. <i>Journal of Colloid and Interface Science</i> , 2019, 545, 162-171.	9.4	21
593	The discovery and development of inhaled therapeutics for migraine. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 591-599.	5.0	4
594	Minocycline and Silver Dual-Loaded Polyphosphoester-Based Nanoparticles for Treatment of Resistant <i>Pseudomonas aeruginosa</i> . <i>Molecular Pharmaceutics</i> , 2019, 16, 1606-1619.	4.6	22
595	Drug delivery for traditional and emerging airway models. <i>Organs-on-a-Chip</i> , 2019, 1, 100002.	3.2	19
596	Toxicological considerations of clinically applicable nanoparticles. , 2019, , 425-483.		2
597	A STELLA simulation model for in vitro dissolution testing of respirable size particles. <i>Scientific Reports</i> , 2019, 9, 18522.	3.3	10
598	Therapeutic efficacy of nanoparticles and routes of administration. <i>Biomaterials Research</i> , 2019, 23, 20.	6.9	561
599	Nanocarrier-based targeted pulmonary delivery: novel approaches for effective lung cancer treatment. , 2019, , 129-161.		4
600	Attenuation of murine and human airway contraction by a peptide fragment of the cytoskeleton regulatory protein gelsolin. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L105-L113.	2.9	2
601	Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 54, 1-21.	2.6	28
602	Mycobactericidal activity of some micro-encapsulated synthetic Host Defense Peptides (HDP) by expediting the permeation of antibiotic: A new paradigm of drug delivery for tuberculosis. <i>International Journal of Pharmaceutics</i> , 2019, 558, 231-241.	5.2	15
603	Can bioactive glasses be useful to accelerate the healing of epithelial tissues?. <i>Materials Science and Engineering C</i> , 2019, 97, 1009-1020.	7.3	74

#	ARTICLE	IF	CITATIONS
604	Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler. British Journal of Clinical Pharmacology, 2019, 85, 580-589.	2.4	7
605	Development of levofloxacin-loaded PLGA microspheres of suitable properties for sustained pulmonary release. International Journal of Pharmaceutics, 2019, 556, 117-124.	5.2	36
606	Non-invasive delivery strategies for biologics. Nature Reviews Drug Discovery, 2019, 18, 19-40.	46.4	397
607	Future of nanomedicines for treating respiratory diseases. Expert Opinion on Drug Delivery, 2019, 16, 59-68.	5.0	19
608	Supercritical Fluid-Assisted Porous Microspheres for Efficient Delivery of Insulin and Inhalation Therapy of Diabetes. Advanced Healthcare Materials, 2019, 8, e1800910.	7.6	26
609	Targeted Drug Delivery to Upper Airways Using a Pulsed Aerosol Bolus and Inhaled Volume Tracking Method. Flow, Turbulence and Combustion, 2019, 102, 73-87.	2.6	24
610	Development of Inhalable Dry Gene Powders for Pulmonary Drug Delivery by Spray-Freeze-Drying. IFMBE Proceedings, 2020, , 533-537.	0.3	1
611	Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. ACS Medicinal Chemistry Letters, 2020, 11, 316-321.	2.8	3
612	Acoustically enhanced evaporation of a polydisperse stream of micro water droplets. Journal of Aerosol Science, 2020, 139, 105466.	3.8	10
613	Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1586.	6.1	60
614	Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. Drug Discovery Today, 2020, 25, 150-159.	6.4	130
615	Physicochemical and Pharmacokinetic Evaluation of Spray-Dried Coformulation of <i>Salvia miltiorrhiza</i> Polyphenolic Acid and L-Leucine with Improved Bioavailability. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 73-82.	1.4	12
616	Engineering of Nebulized Metal-Phenolic Capsules for Controlled Pulmonary Deposition. Advanced Science, 2020, 7, 1902650.	11.2	46
617	Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases. Drug Delivery and Translational Research, 2020, 10, 339-353.	5.8	27
618	Therapeutic effects of nebulized verapamil on chronic obstructive pulmonary disease: A randomized and double-blind clinical trial. Clinical Respiratory Journal, 2020, 14, 370-381.	1.6	4
619	Dose-related effects of inhaled essential oils on behavioural measures of anxiety and depression and biomarkers of oxidative stress. Journal of Ethnopharmacology, 2020, 250, 112469.	4.1	20
620	In vitro toxicity screening of polyglycerol esters of fatty acids as excipients for pulmonary formulations. Toxicology and Applied Pharmacology, 2020, 386, 114833.	2.8	5
621	Polymeric Nanoparticles. , 2020, , 303-324.		23

#	ARTICLE	IF	CITATIONS
622	Lipid nanoparticles biocompatibility and cellular uptake in a 3D human lung model. <i>Nanomedicine</i> , 2020, 15, 259-271.	3.3	15
623	Construction of a Live-Attenuated Vaccine Strain of <i>Yersinia pestis</i> EV76-B-SHU1"pla and Evaluation of Its Protection Efficacy in a Mouse Model by Aerosolized Intratracheal Inoculation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 473.	3.9	9
624	Pulmonary administration of resveratrol/hydroxypropyl- β -cyclodextrin inclusion complex: in vivo disposition and in vitro metabolic study. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 60, 101995.	3.0	4
625	The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 30, 102291.	3.3	22
626	Impedance Spectroscopy for Enhanced Data Collection of Conductometric Soot Sensors. , 2020, , .		0
627	Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 983-1000.	5.0	13
628	Effect of water microdroplet size on the removal of indoor particulate matter. <i>Building and Environment</i> , 2020, 181, 107097.	6.9	7
629	Bioresponsive drug delivery systems for the treatment of inflammatory diseases. <i>Journal of Controlled Release</i> , 2020, 327, 641-666.	9.9	97
630	Designing inhalable metal organic frameworks for pulmonary tuberculosis treatment and theragnostics<i>via</i>spray drying. <i>Chemical Communications</i> , 2020, 56, 13339-13342.	4.1	9
631	Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. <i>Journal of Controlled Release</i> , 2020, 326, 222-244.	9.9	52
632	Comparative anti-inflammatory effect of curcumin at air-liquid interface and submerged conditions using lipopolysaccharide stimulated human lung epithelial A549 cells. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 63, 101939.	2.6	15
633	Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit<i>Pseudomonas aeruginosa</i>-induced inflammation and biofilm formation. <i>Nanomedicine</i> , 2020, 15, 2933-2953.	3.3	21
634	Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 38989-39004.	8.0	102
635	Inhaled nanoparticles- An updated review. <i>International Journal of Pharmaceutics</i> , 2020, 587, 119671.	5.2	51
636	Heater for Controlled Evaporation of Liquids for Personalized Drug Delivery to the Lungs. <i>Journal of Microelectromechanical Systems</i> , 2020, 29, 984-989.	2.5	1
637	In silico optimization of targeted aerosol delivery in upper airways via Inhaled Volume Tracking. <i>Clinical Biomechanics</i> , 2020, 80, 105138.	1.2	6
638	Pulmonary Delivery of Biological Drugs. <i>Pharmaceutics</i> , 2020, 12, 1025.	4.5	97
639	Preclinical Development of Orally Inhaled Drugs (OIDs)-Are Animal Models Predictive or Shall We Move Towards In Vitro Non-Animal Models?. <i>Animals</i> , 2020, 10, 1259.	2.3	23

#	ARTICLE	IF	CITATIONS
640	A Review: The Prospect of Inhaled Insulin Therapy via Vibrating Mesh Technology to Treat Diabetes. International Journal of Environmental Research and Public Health, 2020, 17, 5795.	2.6	12
641	Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals. Pharmaceutics, 2020, 12, 1184.	4.5	55
642	Simple Method to Measure the Aerodynamic Size Distribution of Porous Particles Generated on Lyophilizate for Dry Powder Inhalation. Pharmaceutics, 2020, 12, 976.	4.5	15
643	Size resolved aerosol respiratory doses in a Mediterranean urban area: From PM10 to ultrafine particles. Environment International, 2020, 141, 105714.	10.0	26
644	Drug Absorption Parameters Obtained Using the Isolated Perfused Rat Lung Model Are Predictive of Rat In Vivo Lung Absorption. AAPS Journal, 2020, 22, 71.	4.4	16
645	Pulmonary delivery of a p38 α/β MAP kinase inhibitor: bioanalytical method validation and biodistribution in rat plasma and respiratory tissues. European Journal of Pharmaceutical Sciences, 2020, 149, 105341.	4.0	2
646	Molecular and cellular cues governing nanomaterial-mucosae interactions: from nanomedicine to nanotoxicology. Chemical Society Reviews, 2020, 49, 5058-5100.	38.1	39
647	Characterization of a new aerosol antibiotic/adjuvant combination for the treatment of P. aeruginosa lung infections. International Journal of Pharmaceutics, 2020, 586, 119548.	5.2	8
648	Therapeutic Efficacy of Novel Antimicrobial Peptide AA139-Nanomedicines in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia-Septicemia Model in Rats. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	14
649	Design and Characterizations of Inhalable Poly(lactic-co-glycolic acid) Microspheres Prepared by the Fine Droplet Drying Process for a Sustained Effect of Salmon Calcitonin. Molecules, 2020, 25, 1311.	3.8	12
650	In Silico Optimization of Fiber-Shaped Aerosols in Inhalation Therapy for Augmented Targeting and Deposition across the Respiratory Tract. Pharmaceutics, 2020, 12, 230.	4.5	18
651	Enhanced pulmonary systemic delivery of protein drugs via zwitterionic polymer conjugation. Journal of Controlled Release, 2020, 322, 170-176.	9.9	28
652	Graphene Oxide Nanosheets for Localized Hyperthermia-Physicochemical Characterization, Biocompatibility, and Induction of Tumor Cell Death. Cells, 2020, 9, 776.	4.1	16
653	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Science Translational Medicine, 2020, 12, .	12.4	58
654	Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Delivery, 2020, 17, 635-646.	5.0	39
655	Nebulization Criteria and Quantification. Fluids, 2020, 5, 91.	1.7	2
656	Nanotechnology for pulmonary and nasal drug delivery. , 2020, , 561-579.		4
657	Using Polar Ion-Pairs to Control Drug Delivery to the Airways of the Lungs. Molecular Pharmaceutics, 2020, 17, 1482-1490.	4.6	4

#	ARTICLE	IF	CITATIONS
659	Recent progress in design and preparation of glucose-responsive insulin delivery systems. <i>Journal of Controlled Release</i> , 2020, 321, 236-258.	9.9	72
660	Inhaled milrinone in cardiac surgical patients: a pilot randomized controlled trial of jet vs. mesh nebulization. <i>Scientific Reports</i> , 2020, 10, 2069.	3.3	17
661	Towards whole-lung simulations of aerosol deposition: A model of the deep lung. <i>Journal of Aerosol Science</i> , 2020, 144, 105541.	3.8	44
662	Deposition of bronchiole-originated droplets in the lower airways during exhalation. <i>Journal of Aerosol Science</i> , 2020, 142, 105524.	3.8	8
663	Pulmonary Metabolism of Substrates for Key Drug-Metabolizing Enzymes by Human Alveolar Type II Cells, Human and Rat Lung Microsomes, and the Isolated Perfused Rat Lung Model. <i>Pharmaceutics</i> , 2020, 12, 117.	4.5	14
664	Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2376.	2.5	13
665	High frequency acoustic nebulization for pulmonary delivery of antibiotic alternatives against <i>Staphylococcus aureus</i> . <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 151, 181-188.	4.3	18
666	Caffeine inhalation effects on locomotor activity in mice. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 788-794.	2.0	3
667	Applications of Chitosan in Pulmonary Drug Delivery. , 0, , .		5
668	The promising expedition of the delivery systems for monoclonal antibodies. , 2020, , 69-103.		0
669	Realizing Lobe-Specific Aerosol Targeting in a 3D-Printed <i>In Vitro</i> Lung Model. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2021, 34, 42-56.	1.4	14
670	Building three-dimensional lung models for studying pharmacokinetics of inhaled drugs. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 386-395.	13.7	44
671	Pulmonary Targeting Crosslinked Cyclodextrin Metal-Organic Frameworks for Lung Cancer Therapy. <i>Advanced Functional Materials</i> , 2021, 31, 2004550.	14.9	35
673	Milling of poorly soluble crystalline drug compounds to generate appropriate particle sizes for inhaled sustained drug delivery. <i>International Journal of Pharmaceutics</i> , 2021, 593, 120116.	5.2	9
674	Microfluidic fabrication of inhalable large porous microspheres loaded with H ₂ S-releasing aspirin derivative for pulmonary arterial hypertension therapy. <i>Journal of Controlled Release</i> , 2021, 329, 286-298.	9.9	30
675	Invited review: human air-liquid-interface organotypic airway tissue models derived from primary tracheobronchial epithelial cells—overview and perspectives. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2021, 57, 104-132.	1.5	71
677	Perspectives on Lung Dose and Inhaled Biomolecules. <i>Toxicologic Pathology</i> , 2021, 49, 378-385.	1.8	6
678	Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. <i>Seminars in Cancer Biology</i> , 2021, 69, 166-177.	9.6	197

#	ARTICLE	IF	CITATIONS
679	Nanoparticle Formulations and Delivery Strategies for Sustained Drug Release in the Lungs. , 2021, , 273-300.		0
680	Measurement of Transcellular Transport Rates and Intracellular Drug Sequestration in the Presence of an Extracellular Concentration Gradient. Methods in Pharmacology and Toxicology, 2021, , 3-39.	0.2	0
681	An Overview of New Strategies Based on Functional Nanoscale Materials to the Treatment of Tuberculosis. Engineering Materials, 2021, , 567-590.	0.6	0
682	Application of Nanotechnology in the COVID-19 Pandemic. International Journal of Nanomedicine, 2021, Volume 16, 623-649.	6.7	60
684	Toward all aerosol printing of high-efficiency organic solar cells using environmentally friendly solvents in ambient air. Journal of Materials Chemistry A, 2021, 9, 17198-17210.	10.3	16
685	Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chemical Society Reviews, 2021, 50, 5397-5434.	38.1	398
686	Consideration of Metal Organic Frameworks for Respiratory Delivery. KONA Powder and Particle Journal, 2021, 38, 136-154.	1.7	3
687	Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections. Nanoscale Advances, 2021, 3, 4005-4018.	4.6	24
688	Recent applications and strategies in nanotechnology for lung diseases. Nano Research, 2021, 14, 2067-2089.	10.4	49
689	Physiologically-based pharmacokinetic modeling after drug inhalation. , 2021, , 319-358.		2
690	Droplet Size and Distribution of Nebulized 3% Sodium Chloride, Albuterol, and Epoprostenol by Phase Doppler Particle Analyzer. Current Therapeutic Research, 2021, 94, 100623.	1.2	6
691	In-air particle generation by on-chip electrohydrodynamics. Lab on A Chip, 2021, 21, 1779-1787.	6.0	11
692	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opinion on Drug Delivery, 2021, 18, 891-906.	5.0	7
693	Cellular and functional heterogeneity of the airway epithelium. Mucosal Immunology, 2021, 14, 978-990.	6.0	109
694	Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned. Respiratory Research, 2021, 22, 71.	3.6	29
696	Inhaled fixed-dose combination powders for the treatment of respiratory infections. Expert Opinion on Drug Delivery, 2021, 18, 1101-1115.	5.0	12
697	Regional Deposition: Targeting. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2021, 34, 1-10.	1.4	11
698	Systemic Delivery of hChrelin Derivative by Lyophilizate for Dry Powder Inhalation System in Monkeys. Pharmaceutics, 2021, 13, 233.	4.5	4

#	ARTICLE	IF	CITATIONS
699	Controlled Pulmonary Delivery of Carrier-Free Budesonide Dry Powder by Atomic Layer Deposition. ACS Nano, 2021, 15, 6684-6698.	14.6	25
700	Aerosol-based Pulmonary Delivery of Therapeutic Molecules from Food Sources: Delivery Mechanism, Research Trends, and the Way Forward. Food Reviews International, 0, , 1-36.	8.4	1
701	Co-delivery of inhalable therapies: Controlling active ingredients spatial distribution and temporal release. Materials Science and Engineering C, 2021, 122, 111831.	7.3	2
702	Design of polymeric core-shell carriers for combination therapies. Journal of Colloid and Interface Science, 2021, 587, 499-509.	9.4	14
703	Using Rotenone to Model Parkinson's Disease in Mice: A Review of the Role of Pharmacokinetics. Chemical Research in Toxicology, 2021, 34, 1223-1239.	3.3	43
704	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Science Advances, 2021, 7, .	10.3	113
705	Injectable Temperature/Glucose Dual-Responsive Hydrogels for Controlled Release of Insulin. Industrial & Engineering Chemistry Research, 2021, 60, 8147-8158.	3.7	20
707	Novel formulations and drug delivery systems to administer biological solids. Advanced Drug Delivery Reviews, 2021, 172, 183-210.	13.7	25
708	Dry powder pharmaceutical biologics for inhalation therapy. Advanced Drug Delivery Reviews, 2021, 172, 64-79.	13.7	53
709	Prospects of Neutralizing Nanobodies Against SARS-CoV-2. Frontiers in Immunology, 2021, 12, 690742.	4.8	22
710	Understanding the Impact of Protein-Excipient Interactions on Physical Stability of Spray-Dried Protein Solids. Molecular Pharmaceutics, 2021, 18, 2657-2668.	4.6	24
711	Effects of Varying Inhalation Duration and Respiratory Rate on Human Airway Flow. Fluids, 2021, 6, 221.	1.7	7
712	An Overview on Atomization and Its Drug Delivery and Biomedical Applications. Applied Sciences (Switzerland), 2021, 11, 5173.	2.5	8
713	Predictive Platforms of Bond Cleavage and Drug Release Kinetics for Macromolecule-Drug Conjugates. Annual Review of Chemical and Biomolecular Engineering, 2021, 12, 241-261.	6.8	7
714	Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process. Pharmaceutics, 2021, 13, 1051.	4.5	2
715	Inhalable liposomes for treating lung diseases: clinical development and challenges. Biomedical Materials (Bristol), 2021, 16, 054101.	3.3	13
716	Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update. Pharmaceutics, 2021, 14, 725.	3.8	24
717	The next generation therapy for lung cancer: taking medicine by inhalation. Nanotechnology, 2021, 32, 392002.	2.6	6

#	ARTICLE	IF	CITATIONS
718	Nebulization of Risedronate Sodium Microspheres for Potential Attenuation of Pulmonary Emphysema: a Promising New Insight of Alveolar Macrophage Apoptosis. AAPS PharmSciTech, 2021, 22, 202.	3.3	3
719	Engineering of konjac glucomannan into respirable microparticles for delivery of antitubercular drugs. International Journal of Pharmaceutics, 2021, 604, 120731.	5.2	18
720	Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 164, 36-53.	4.3	1
721	Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic. Nanomaterials, 2021, 11, 1841.	4.1	18
722	Study on Deposition Characteristics of Microparticles in Terminal Pulmonary Acini by IBâ€‘LBM. Micromachines, 2021, 12, 957.	2.9	3
723	Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption. Clinical Pharmacokinetics, 2022, 61, 281-293.	3.5	8
724	Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Review of Vaccines, 2022, 21, 957-974.	4.4	51
725	Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharmaceutica Sinica B, 2021, 11, 2565-2584.	12.0	63
726	Identification of Stability Constraints in the Particle Engineering of an Inhaled Monoclonal Antibody Dried Powder. Journal of Pharmaceutical Sciences, 2022, 111, 403-416.	3.3	9
727	Translation of pulmonary protein therapy from bench to bedside: Addressing the bioavailability challenges. Journal of Drug Delivery Science and Technology, 2021, 64, 102664.	3.0	6
728	A resource of high-quality and versatile nanobodies for drug delivery. IScience, 2021, 24, 103014.	4.1	19
729	The rough inhalable ciprofloxacin hydrochloride microparticles based on silk fibroin for non-cystic fibrosis bronchiectasis therapy with good biocompatibility. International Journal of Pharmaceutics, 2021, 607, 120974.	5.2	4
730	Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective. Drug Discovery Today, 2022, 27, 134-150.	6.4	17
731	Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics. Advanced Drug Delivery Reviews, 2021, 176, 113901.	13.7	27
732	In vitro and ex vivo models in inhalation biopharmaceutical research â€” advances, challenges and future perspectives. Advanced Drug Delivery Reviews, 2021, 177, 113862.	13.7	38
733	Mesoporous silica nanoparticles for pulmonary drug delivery. Advanced Drug Delivery Reviews, 2021, 177, 113953.	13.7	64
734	Organic cation transporters (OCTs/OCTNs) in human primary alveolar epithelial cells. Biochemical and Biophysical Research Communications, 2021, 576, 27-32.	2.1	5
735	Pulmonary circulation-mediated heart targeting for the prevention of heart failure by inhalation of intrinsically bioactive nanoparticles. Theranostics, 2021, 11, 8550-8569.	10.0	21

#	ARTICLE	IF	CITATIONS
736	Multimodal imaging of drug and excipients in rat lungs following an inhaled administration of controlled-release drug laden PLGA microparticles. <i>Analyst</i> , The, 2021, 146, 3378-3390.	3.5	3
737	Co-administration of Luteolin mitigated toxicity in rats' lungs associated with doxorubicin treatment. <i>Toxicology and Applied Pharmacology</i> , 2021, 411, 115380.	2.8	20
738	In Vitro Models of the Tracheo-Bronchial Epithelium. , 2008, , 235-257.		13
739	The Isolated Perfused Lung for Drug Absorption Studies. , 2008, , 135-163.		9
740	Biological Barriers: Transdermal, Oral, Mucosal, Blood Brain Barrier, and the Blood Eye Barrier. , 2013, , 301-336.		4
741	Archaeobacterial Tetraetherlipid Liposomes. <i>Methods in Molecular Biology</i> , 2010, 605, 87-96.	0.9	6
742	Evaluation of Lung Toxicity of Biodegradable Nanoparticles. <i>Advances in Delivery Science and Technology</i> , 2015, , 689-732.	0.4	1
743	Crystal Nucleation of Small Organic Molecules. , 2017, , 317-337.		5
744	Pharmacodynamic Evaluation: Diabetes Methodologies. , 2011, , 457-481.		9
745	Advances in Pulmonary Nanomedicine for Therapeutic Management of Respiratory Diseases. , 2020, , 237-266.		2
746	Aerosols and Aerosol Drug Delivery Systems. , 2009, , 679-700.		1
747	Mannose-anchored N,N,N-trimethyl chitosan nanoparticles for pulmonary administration of etofylline. <i>International Journal of Biological Macromolecules</i> , 2020, 165, 445-459.	7.5	36
748	Development of inhaled formulation of modified clofazimine as an alternative to treatment of tuberculosis. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 58, 101805.	3.0	9
749	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1742-1764.	5.2	16
750	Nanostructures for Overcoming the Pulmonary Barrier: Drug Delivery Strategies. <i>RSC Drug Discovery Series</i> , 2012, , 273-299.	0.3	2
751	Formulation development, <i>in vitro</i> and <i>in vivo</i> evaluation of chitosan engineered nanoparticles for ocular delivery of insulin. <i>RSC Advances</i> , 2020, 10, 43629-43639.	3.6	24
752	The Development and Validation of an In Vitro Airway Model to Assess Realistic Airway Deposition and Drug Permeation Behavior of Orally Inhaled Products Across Synthetic Membranes. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018, 31, 103-108.	1.4	3
754	Study of the flow unsteadiness in the human airway using large eddy simulation. <i>Physical Review Fluids</i> , 2017, 2, .	2.5	18

#	ARTICLE	IF	CITATIONS
756	Inhaled Proteins and Peptides. , 2016, , 1-22.		1
757	Pulmonary Drug Delivery with Nanoparticles. , 2011, , .		1
758	Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions. Chemical and Pharmaceutical Bulletin, 2020, 68, 589-602.	1.3	10
759	A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs. PLoS Computational Biology, 2020, 16, e1008466.	3.2	6
760	Metabolic Hormones, Apolipoproteins, Adipokines, and Cytokines in the Alveolar Lining Fluid of Healthy Adults: Compartmentalization and Physiological Correlates. PLoS ONE, 2015, 10, e0123344.	2.5	15
761	Towards Standardized Dissolution Techniques for In Vitro Performance Testing of Dry Powder Inhalers. Dissolution Technologies, 2018, 25, 6-18.	0.6	20
762	Applications of the Atomic Force Microscope in the Development of Propellant-based Inhalation Formulations. KONA Powder and Particle Journal, 2008, 26, 106-128.	1.7	5
763	Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology. ALTEX: Alternatives To Animal Experimentation, 2015, 32, 327-378.	1.5	108
765	Preparation and Characterization of Celecoxib Agglomerated Nanocrystals and Dry Powder Inhalation Formulations to Improve its Aerosolization Performance. Pharmaceutical Sciences, 2017, 23, 278-284.	0.2	2
766	Feasibility of Aerosolized Alpha-1 Antitrypsin as a Therapeutic Option. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 272-279.	0.7	6
767	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget, 2017, 8, 29613-29624.	1.8	9
768	Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics: Targets and Therapy, 2009, 3, 193.	3.2	58
769	Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals. Current Pharmaceutical Design, 2015, 21, 2599-2610.	1.9	16
770	Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives. Current Pharmaceutical Design, 2015, 21, 5233-5244.	1.9	52
771	Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery. Current Pharmaceutical Design, 2016, 22, 2463-2469.	1.9	37
772	Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We?. Current Pharmaceutical Design, 2016, 22, 2561-2576.	1.9	16
773	The Applications of 3D Printing in Pulmonary Drug Delivery and Treatment of Respiratory Disorders. Current Pharmaceutical Design, 2019, 24, 5072-5080.	1.9	5
774	Nanocarriers for Respiratory Diseases Treatment: Recent Advances and Current Challenges. Current Topics in Medicinal Chemistry, 2014, 14, 1133-1147.	2.1	14

#	ARTICLE	IF	CITATIONS
775	Recent Patents in Pulmonary Delivery of Macromolecules. Recent Patents on Drug Delivery and Formulation, 2015, 9, 230-241.	2.1	13
776	Nanoparticles in the treatment of chronic lung diseases. Journal of Mind and Medical Sciences, 2019, 6, 224-231.	0.4	19
777	Development of Otsuka dry powder inhalation system using technology of freeze-drying. Drug Delivery System, 2009, 24, 468-476.	0.0	5
778	Nanotechnologies in development of pulmonary drug delivery. Drug Delivery System, 2009, 24, 477-483.	0.0	3
779	Prediction of Aerosol Deposition in the Human Respiratory Tract via Computational Models: A Review with Recent Updates. Atmosphere, 2020, 11, 137.	2.3	29
780	Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Dry Powders of Lactomorphin for Respiratory Delivery: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies. Pharmaceutics, 2021, 13, 26.	4.5	9
781	Now Take a Deep Breath: Inhaled Loxapine for the Treatment of Acute Agitation. Journal of Psychosocial Nursing and Mental Health Services, 2012, 50, 16-18.	0.6	1
782	Newer drug delivery systems in anesthesia. Journal of Anaesthesiology Clinical Pharmacology, 2017, 33, 157.	0.7	11
783	Current Development in the Evaluation Methods of Pulmonary Drug Delivery System. Indian Journal of Pharmaceutical Sciences, 2016, 78, .	1.0	7
784	Preparation of Highly Porous Poly(d,l-lactic-co-glycolic acid) (PLGA) Microspheres. Journal of Korean Pharmaceutical Sciences, 2009, 39, 167-171.	0.0	1
785	Nanomaterials and the human lung: what is known and what must be deciphered to realise their potential advantages?. Swiss Medical Weekly, 2013, 143, w13758.	1.6	21
786	Nanotechnology Based Targeted Drug Delivery: Current Status and Future Prospects for Drug Development. , 0, , .		5
787	Polysaccharide-based formulations as potential carriers for pulmonary delivery – A review of their properties and fates. Carbohydrate Polymers, 2022, 277, 118784.	10.2	22
788	Are Plant-Based Carbohydrate Nanoparticles Safe for Inhalation? Investigating Their Interactions with the Pulmonary Surfactant Using Langmuir Monolayers. Langmuir, 2021, 37, 12365-12376.	3.5	3
789	Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19. Asian Journal of Pharmaceutical Sciences, 2021, 16, 772-783.	9.1	26
790	The use of heat to deliver fentanyl via pulmonary drug delivery. International Journal of Pharmaceutics: X, 2021, 3, 100096.	1.6	1
791	Short Inhalation Exposures of the Isolated and Perfused Rat Lung to Respirable Dry Particle Aerosols; The Detailed Pharmacokinetics of Budesonide, Formoterol, and Terbutaline. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
792	Targeting Drugs to the Lungs – The Example of Insulin. , 2010, , 227-249.		0

#	ARTICLE	IF	CITATIONS
793	Administraci3n de f3rmacos por v3a inhalatoria. , 2010, , 83-92.		0
795	The Delivery of Drugs �� Peptides and Proteins. , 2011, , 576-593.		2
796	Intracellular Bacteria and Protozoa. Fundamental Biomedical Technologies, 2011, , 745-811.	0.2	0
797	Prediction of Toxicity, Sensory Responses and Biological Responses with the Abraham Model. , 0, , .		1
798	Novel Concept in Pulmonary Delivery. , 0, , .		1
800	Inhaler Systems: Dry Powder. , 0, , 4063-4074.		0
802	Pulmonary Drug Delivery. , 2016, , 249-277.		0
803	Smart Biomaterials in Drug Delivery Applications. , 2016, , 65-93.		0
804	Market Scenario of Biomaterial-Based Devices. , 2016, , 207-217.		1
807	Preparation of Spray-Dried Nanoparticles for Efficient Drug Delivery to the Lungs. Methods in Molecular Biology, 2020, 2118, 139-145.	0.9	2
808	Optimization of swirler type dry powder inhaler device design �� Numerical investigation on the effect of dimple shape, inlet configuration and mouthpiece constriction. Journal of Aerosol Science, 2022, 159, 105893.	3.8	2
809	Systematic Combination of Oligonucleotides and Synthetic Polymers for Advanced Therapeutic Applications. Macromolecular Research, 2021, 29, 665-680.	2.4	7
811	NEBULIZERS: AERODYNAMIC DROPLET DIAMETER CHARACTERIZATION AND PHYSICOCHEMICAL PROPERTIES OF DRUGS TO TREAT SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2). International Journal of Research -GRANTHAALAYAH, 2020, 8, 80-97.	0.1	3
812	Engineering Preclinical Tools and Therapeutics to Understand and Treat COVID-19. Delaware Journal of Public Health, 2020, 6, 32-35.	0.3	0
813	Cilia proteins CFAP36 and sentan in induced sputum as possible new markers of epithelial damage in obstructive lung diseases: A preliminary study. Postepy Higieny I Medycyny Doswiadczalnej, 2020, 74, 437-442.	0.1	1
817	A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19. Iranian Journal of Medical Sciences, 2021, 46, 151-168.	0.4	2
818	Design and evaluation of folate-modified liposomes for pulmonary administration in lung cancer therapy. European Journal of Pharmaceutical Sciences, 2022, 168, 106081.	4.0	11
819	Bridging micro/nano-platform and airway allergy intervention. Journal of Controlled Release, 2022, 341, 364-382.	9.9	7

#	ARTICLE	IF	CITATIONS
820	Nebulizer systems: a new frontier for therapeutics and targeted delivery. <i>Therapeutic Delivery</i> , 2022, 13, 31-49.	2.2	10
821	3D Bioprinting Strategies, Challenges, and Opportunities to Model the Lung Tissue Microenvironment and Its Function. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 773511.	4.1	32
822	Immobilization and Intracellular Delivery of Structurally Nanoengineered Antimicrobial Peptide Polymers Using Polyphenol-Based Capsules. <i>Advanced Functional Materials</i> , 2022, 32, 2107341.	14.9	19
823	Drug Meets Monolayer: Understanding the Interactions of Sterol Drugs with Models of the Lung Surfactant Monolayer Using Molecular Dynamics Simulations. <i>Methods in Molecular Biology</i> , 2022, 2402, 103-121.	0.9	2
824	Microspheres Based on a Protein Matrix and Dipyridamole with Possible Inhalation Administration. <i>Pharmaceutical Chemistry Journal</i> , 0, , 1.	0.8	3
825	Inhalable mRNA vaccines for respiratory diseases: a roadmap. <i>Current Opinion in Biotechnology</i> , 2022, 74, 104-109.	6.6	10
826	Alveolar macrophages: novel therapeutic targets for respiratory diseases. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e18.	3.9	10
827	Unraveling the pulmonary drug delivery carriers in inhalable nanostructures. <i>Journal of Nanoparticle Research</i> , 2022, 24, 10.	1.9	2
828	Tuning the membrane fluidity of liposomes for desirable in vivo fate with enhanced drug delivery. <i>Advances in Biomembranes and Lipid Self-Assembly</i> , 2021, 34, 67-106.	0.6	7
829	PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats. <i>Journal of Controlled Release</i> , 2022, 342, 44-52.	9.9	11
830	Complete Protection Against <i>Yersinia pestis</i> in BALB/c Mouse Model Elicited by Immunization With Inhalable Formulations of rF1-V10 Fusion Protein via Aerosolized Intratracheal Inoculation. <i>Frontiers in Immunology</i> , 2022, 13, 793382.	4.8	3
831	Gene Therapy for Acute Respiratory Distress Syndrome. <i>Frontiers in Physiology</i> , 2021, 12, 786255.	2.8	4
832	Integrative Metabolomics, Proteomics and Transcriptomics Analysis Reveals Liver Toxicity of Mesoporous Silica Nanoparticles. <i>Frontiers in Pharmacology</i> , 2022, 13, 835359.	3.5	8
833	Treatment of Tuberculosis in Nano Era: Recent Avenues. <i>Current Bioactive Compounds</i> , 2022, 18, .	0.5	1
834	Prospective nanoparticle treatments for lymphangioleiomyomatosis. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 75-86.	5.0	1
835	Enabling customer-centric and sustainable drug delivery” formulation and device lifecycle management of biotherapeutics. , 2022, , 1-46.		1
836	PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101536.	7.6	26
837	Applications and Biocompatibility of Mesoporous Silica Nanocarriers in the Field of Medicine. <i>Frontiers in Pharmacology</i> , 2022, 13, 829796.	3.5	13

#	ARTICLE	IF	CITATIONS
838	Glucose sensitive konjac glucomannan/concanavalin A nanoparticles as oral insulin delivery system. International Journal of Biological Macromolecules, 2022, 202, 296-308.	7.5	16
839	Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. Journal of the Neurological Sciences, 2022, 434, 120152.	0.6	11
840	Models using native tracheobronchial mucus in the context of pulmonary drug delivery research: Composition, structure and barrier properties. Advanced Drug Delivery Reviews, 2022, 183, 114141.	13.7	17
841	Medicinal chemistry strategies to extend duration of action of inhaled drugs for intracellular targets. Bioorganic and Medicinal Chemistry Letters, 2022, 62, 128627.	2.2	17
842	Biodegradable Materials for Medicinal Applications. Materials Horizons, 2022, , 247-261.	0.6	0
843	Nano-Bio Interactions in the Lung. Micro/Nano Technologies, 2022, , 1-31.	0.1	1
844	Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics. Drug Metabolism and Disposition, 2022, 50, 867-878.	3.3	3
845	To Enhance Mucus Penetration and Lung Absorption of Drug by Inhalable Nanocrystals-In-Microparticles. Pharmaceutics, 2022, 14, 538.	4.5	7
846	Nanocrystals based pulmonary inhalation delivery system: advance and challenge. Drug Delivery, 2022, 29, 637-651.	5.7	21
847	Shape-specific microfabricated particles for biomedical applications: a review. Drug Delivery and Translational Research, 2022, 12, 2019-2037.	5.8	8
848	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell, 2022, 185, 1389-1401.e18.	28.9	82
849	Ultrasound-Assisted Slug-Flow Tubular Crystallization for Preparation of Fine Ibuprofen Crystals. Chemical Engineering and Technology, 2022, 45, 727-736.	1.5	4
851	Development and Study of Ezzence: A Modular Scent Wearable to Improve Wellbeing in Home Sleep Environments. Frontiers in Psychology, 2022, 13, 791768.	2.1	7
852	Radiolabeling Method for Lyophilizate for Dry Powder Inhalation Formulations. Pharmaceutics, 2022, 14, 759.	4.5	0
853	Pulmonary vaccine delivery: An emerging strategy for vaccination and immunotherapy. Journal of Drug Delivery Science and Technology, 2022, 69, 103184.	3.0	6
854	Inhalable cryptotanshinone spray-dried swellable microparticles for pulmonary fibrosis therapy by regulating TGF- β 1/Smad3, STAT3 and SIRT3 pathways. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 172, 177-192.	4.3	10
855	Modeling insights into SARS-CoV-2 respiratory tract infections prior to immune protection. Biophysical Journal, 2022, 121, 1619-1631.	0.5	17
856	Spray Dried Rugose Lipid Particle Platform for Respiratory Drug Delivery. Pharmaceutical Research, 2022, 39, 805-823.	3.5	8

#	ARTICLE	IF	CITATIONS
857	Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes. Journal of Controlled Release, 2022, 345, 334-353.	9.9	55
858	Revisiting Airflow and Aerosol Transport Phenomena in the Deep Lungs with Microfluidics. Chemical Reviews, 2022, 122, 7182-7204.	47.7	17
859	Ultra-dispersed particles of water-soluble and water-insoluble substances formed from gas-droplet flows. Journal of Physics: Conference Series, 2021, 2119, 012047.	0.4	0
860	Zinc ions coordinated carboxymethyl chitosan-hyaluronic acid microgel for pulmonary drug delivery. International Journal of Biological Macromolecules, 2021, 193, 1043-1049.	7.5	15
862	Advanced Drug Delivery Systems Targeting the Immune System at Cellular Level in Chronic Respiratory Diseases. , 2022, , 333-358.		1
873	Advances and future perspectives in epithelial drug delivery. Advanced Drug Delivery Reviews, 2022, 186, 114293.	13.7	43
874	Targeted delivery of inhalable drug particles in a patient-specific tracheobronchial tree with moderate COVID-19: A numerical study. Powder Technology, 2022, 405, 117520.	4.2	5
875	High dose nanocrystalline solid dispersion powder of voriconazole for inhalation. International Journal of Pharmaceutics, 2022, 622, 121827.	5.2	1
877	Advances in the design of new types of inhaled medicines. Progress in Medicinal Chemistry, 2022, , 93-162.	10.4	3
878	Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19. ACS Biomaterials Science and Engineering, 2022, 8, 2553-2563.	5.2	9
879	Optimization of Particle Properties of Nanocrystalline Solid Dispersion Based Dry Powder for Inhalation of Voriconazole. Journal of Pharmaceutical Sciences, 2022, 111, 2592-2605.	3.3	4
880	Stability of therapeutic nano-drugs during storage and transportation as well as after ingestion in the human body. , 2022, , 83-102.		2
881	Nebulizer particle size distribution measured by various methods. EPJ Web of Conferences, 2022, 264, 01023.	0.3	2
882	Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge. Pharmaceutics, 2022, 14, 1447.	4.5	5
883	Temperature-Responsive Polysaccharide Microparticles Containing Nanoparticles: Release of Multiple Cationic/Anionic Compounds. Materials, 2022, 15, 4717.	2.9	2
884	Design, Synthesis, and Evaluation of Lung-Retentive Prodrugs for Extending the Lung Tissue Retention of Inhaled Drugs. Journal of Medicinal Chemistry, 2022, 65, 9802-9818.	6.4	2
885	Nebulization of siRNA for inhalation therapy based on a microfluidic surface acoustic wave platform. Ultrasonics Sonochemistry, 2022, 88, 106088.	8.2	9
886	Increasing stiffness promotes pulmonary retention of ligand-directed dexamethasone-loaded nanoparticle for enhanced acute lung inflammation therapy. Bioactive Materials, 2023, 20, 539-547.	15.6	4

#	ARTICLE	IF	CITATIONS
887	Label-free detection and quantification of ultrafine particulate matter in lung and heart of mouse and evaluation of tissue injury. Particle and Fibre Toxicology, 2022, 19, .	6.2	5
888	Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus Monkeys. Pharmaceutical Research, 2022, 39, 2191-2201.	3.5	4
889	Advances in the Discovery of Novel Inhaled PI3K γ Inhibitors for the Treatment of Asthma. Current Medicinal Chemistry, 2023, 30, 1971-1992.	2.4	0
890	Pharmacokinetics of baicalin and oroxyloside in plasma and different tissues of rats after transnasal aerosol inhalation and intravenous injection of Tanreqing. Frontiers in Pharmacology, 0, 13, .	3.5	2
891	Pulmonary delivery of size-transformable nanoparticles improves tumor accumulation and penetration for chemo-sonodynamic combination therapy. Journal of Controlled Release, 2022, 350, 132-145.	9.9	11
892	Spatial aerosol deposition correlated to anatomic feature development in 6-year-old upper airway computational models. Computers in Biology and Medicine, 2022, 149, 106058.	7.0	4
893	Thermoresponsive polysaccharide particles: Control of dissolution and release properties. Journal of Drug Delivery Science and Technology, 2022, 76, 103793.	3.0	0
894	Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspective. Advanced Drug Delivery Reviews, 2022, 190, 114526.	13.7	8
895	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. Biomedical Engineering Advances, 2022, 4, 100054.	3.8	3
896	Chapter 6. Inhalation of Insulin for Diabetes Management. RSC Nanoscience and Nanotechnology, 2022, , 165-187.	0.2	0
897	Factors Affecting Drug Exposure after Inhalation. Prague Medical Report, 2022, 123, 129-139.	0.8	1
898	Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment. Pharmaceutical Research, 2022, 39, 3359-3370.	3.5	2
899	Phenotypic characteristics and protective efficacy of an attenuated Mycoplasma hyopneumoniae vaccine by aerosol administration. Vaccine, 2022, 40, 6074-6083.	3.8	1
900	In-vitro measurement of aerosol generated by Respimat SMI penetrating through upper airways. EPJ Web of Conferences, 2022, 269, 01038.	0.3	0
901	Nuclear medicine imaging methods as novel tools in the assessment of pulmonary drug disposition. Expert Opinion on Drug Delivery, 0, , 1-15.	5.0	4
902	Air Pollution with Fine Particles in Closed Parking and Theoretical Studies of the Interaction of Inhaled Particles in Respiratory Tract. Buildings, 2022, 12, 1696.	3.1	5
903	Alternation of Organ-Specific Exposure in LPS-Induced Pneumonia Mice after the Inhalation of Tetradrine Is Governed by Metabolizing Enzyme Suppression and Lysosomal Trapping. International Journal of Molecular Sciences, 2022, 23, 12948.	4.1	0
904	Polymeric Nanoparticles for Inhaled Vaccines. Polymers, 2022, 14, 4450.	4.5	7

#	ARTICLE	IF	CITATIONS
905	Pharmacologic therapies of ARDS: From natural herb to nanomedicine. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
906	Deciphering the Effects of 2D Black Phosphorus on Disrupted Hematopoiesis and Pulmonary Immune Homeostasis Using a Developed Flow Cytometry Method. <i>Environmental Science & Technology</i> , 2022, 56, 15869-15881.	10.0	5
907	Nanodelivery based Chinese medicine's bioactive compounds for treatment of respiratory disorders. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 5, 100180.	1.2	0
908	Challenges and Strategies to Enhance the Systemic Absorption of Inhaled Peptides and Proteins. <i>Pharmaceutical Research</i> , 2023, 40, 1037-1055.	3.5	10
909	Penetration and translocation of functional inorganic nanomaterials into biological barriers. <i>Advanced Drug Delivery Reviews</i> , 2022, 191, 114615.	13.7	20
910	Mechanistic modeling of generic orally inhaled drug products: A workshop summary report. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 560-574.	2.5	7
911	Emerging Strategies to Improve the Stability and Bioavailability of Insulin: An Update on Formulations and Delivery Approaches. <i>Current Drug Delivery</i> , 2023, 20, 1141-1162.	1.6	5
912	Analyzing proteolytic stability and metabolic hotspots of therapeutic peptides in two rodent pulmonary fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 224, 115156.	2.8	1
913	Particles and microbiota: interaction to death or resilience?., 2023, , 1-48.		0
914	Human lung cell models to study aerosol delivery “considerations for model design and development. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 180, 106337.	4.0	6
915	Dissolution and Absorption of Inhaled Drug Particles in the Lungs. <i>Pharmaceutics</i> , 2022, 14, 2667.	4.5	7
916	Nanovaccines against Viral Infectious Diseases. <i>Pharmaceutics</i> , 2022, 14, 2554.	4.5	6
917	Nanomaterials for Delivering Antibiotics in the Therapy of Pneumonia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15738.	4.1	2
918	A scientometrics study of the nanomedicines assisted in respiratory diseases. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	2
919	Tissue-Targeted Drug Delivery Strategies to Promote Antigen-Specific Immune Tolerance. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	4
920	Identification of potent antimicrobial peptides via a machine-learning pipeline that mines the entire space of peptide sequences. <i>Nature Biomedical Engineering</i> , 2023, 7, 797-810.	22.5	38
921	Nano-bio Interactions in the Lung. <i>Micro/Nano Technologies</i> , 2023, , 469-499.	0.1	0
922	Nebulization of model hydrogel nanoparticles to macrophages at the air-liquid interface. <i>Frontiers in Chemical Engineering</i> , 0, 4, .	2.7	1

#	ARTICLE	IF	CITATIONS
923	Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments. <i>Pharmaceutics</i> , 2023, 15, 139.	4.5	4
924	Clinical applications and future clinical trials of the drug delivery system. , 2023, , 259-294.		0
925	Emergence of Glucomannan and Xyloglucan for Respirable Delivery. , 2023, , 167-181.		0
926	An evolving perspective on novel modified release drug delivery systems for inhalational therapy. Expert Opinion on Drug Delivery, 2023, 20, 335-348.	5.0	3
927	Alginate-Based Inhalable Particles for Controlled Pulmonary Drug Delivery. , 2023, , 207-240.		1
928	Targeted delivery of inhalable drug particles in the tracheobronchial tree model of a pediatric patient with bronchopneumonia: A numerical study. <i>Respiratory Physiology and Neurobiology</i> , 2023, 311, 104024.	1.6	1
929	Influence of P-glycoprotein on pulmonary disposition of the model substrate [11C]metoclopramide assessed by PET imaging in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 183, 106404.	4.0	1
930	N,N,N-Trimethyl chitosan as a permeation enhancer for inhalation drug delivery: Interaction with a model pulmonary surfactant. <i>International Journal of Biological Macromolecules</i> , 2023, 239, 124235.	7.5	3
931	Modeling identifies variability in SARS-CoV-2 uptake and eclipse phase by infected cells as principal drivers of extreme variability in nasal viral load in the 48h post infection. <i>Journal of Theoretical Biology</i> , 2023, 565, 111470.	1.7	5
934	Aluminum-based metal-organic framework nanoparticles as pulmonary vaccine adjuvants. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	9.1	9
935	Nanobodies: Robust miniprotein binders in biomedicine. <i>Advanced Drug Delivery Reviews</i> , 2023, 195, 114726.	13.7	7
937	PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4333.	4.1	10
938	Pulmonary Surfactant-Based Paclitaxel-Loaded Nanovesicles for Inhalation Therapy of Lung Adenocarcinoma. <i>ACS Applied Nano Materials</i> , 2023, 6, 3693-3703.	5.0	1
939	Inhaled milrinone in cardiac surgical patients: pharmacokinetic and pharmacodynamic exploration. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
940	Detection of abused drugs in human exhaled breath using mass spectrometry: A review. <i>Rapid Communications in Mass Spectrometry</i> , 2023, 37, .	1.5	1
941	Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing. <i>Pharmaceutics</i> , 2023, 16, 451.	3.8	9
942	New Routes of Insulin for Diabetes Treatment. <i>International Journal of Advanced Research in Science, Communication and Technology</i> , 0, , 228-241.	0.0	0
943	Polysaccharide-Based Carriers for Pulmonary Insulin Delivery: The Potential of Coffee as an Unconventional Source. <i>Pharmaceutics</i> , 2023, 15, 1213.	4.5	0

#	ARTICLE	IF	CITATIONS
944	Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function. Advanced Drug Delivery Reviews, 2023, 197, 114828.	13.7	7
945	Development and characterization of lung surfactant-coated polymer nanoparticles for pulmonary drug delivery. , 2023, 150, 213430.		2
946	Aerosol pulmonary immune engineering. Advanced Drug Delivery Reviews, 2023, 199, 114831.	13.7	7
947	Routes of Nano-drug Administration and Nano-based Drug Delivery System and Toxicity. , 2023, , 671-702.		0
948	Fullerene-based nanocomplex assists pulmonary delivery of siRNA for treating metastatic lung cancer. Nano Today, 2023, 50, 101878.	11.9	6
949	Nanomedicines: Impactful Approaches for Targeting Pulmonary Diseases. Pharmaceutical Nanotechnology, 2023, 11, .	1.5	0
950	Overview of Inhaled Nanopharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2023, 36, 144-151.	1.4	2
951	Pulmonary Delivery for miRs: Present and Future Potential. Processes, 2023, 11, 1788.	2.8	0
952	Inhaled lipid nanocarriers for pulmonary delivery of glucocorticoids: Previous strategies, recent advances and key factors description. International Journal of Pharmaceutics, 2023, 642, 123146.	5.2	2
953	Delivering monoclonal antibodies via inhalation: a systematic review of clinical trials in asthma and COPD. Expert Opinion on Drug Delivery, 2023, 20, 1041-1054.	5.0	3
954	Polyplex designs for improving the stability and safety of RNA therapeutics. Advanced Drug Delivery Reviews, 2023, 199, 114972.	13.7	6
955	Recent Advances in the Polish Research on Polysaccharide-Based Nanoparticles in the Context of Various Administration Routes. Biomedicines, 2023, 11, 1307.	3.2	0
956	Zwitterionic Inhaler with Synergistic Therapeutics for Reprogramming of M2 Macrophage to Pro- ∞ Inflammatory Phenotype. Advanced Healthcare Materials, 0, , .	7.6	0
957	Aerosol technology to mimic dry powder inhalation in vitro using pulmonary cell models. European Journal of Pharmaceutics and Biopharmaceutics, 2023, 188, 201-216.	4.3	0
958	Advances and Prospects of Prolamine Corn Protein Zein as Promising Multifunctional Drug Delivery System for Cancer Treatment. International Journal of Nanomedicine, 0, Volume 18, 2589-2621.	6.7	5
959	Optimization and Characterization of Novel ALCAM-Targeting Antibody Fragments for Transepithelial Delivery. Pharmaceutics, 2023, 15, 1841.	4.5	0
960	Predicting particle deposition using a simplified 8-path in silico human lung prototype. Journal of Breath Research, 2023, 17, 046002.	3.0	1
961	Systemic Protein Delivery via Inhalable Liposomes: Formulation and Pharmacokinetics. Pharmaceutics, 2023, 15, 1951.	4.5	1

#	ARTICLE	IF	CITATIONS
962	Novel Vectors and Administrations for mRNA Delivery. Small, 2023, 19, .	10.0	3
963	A Pediatric Upper Airway Library to Evaluate Interpatient Variability of In Silico Aerosol Deposition. AAPS PharmSciTech, 2023, 24, .	3.3	2
964	Utilization of endogenous albumin trafficking pathways in the lungs has potential to modestly increase the lung interstitial access and absorption of drug delivery systems after inhaled administration. Expert Opinion on Drug Delivery, 2023, 20, 1145-1155.	5.0	1
965	Biosafety of mesoporous silica nanoparticles; towards clinical translation. Advanced Drug Delivery Reviews, 2023, 201, 115049.	13.7	16
966	Barriers for orally inhaled therapeutic antibodies. Expert Opinion on Drug Delivery, 2023, 20, 1071-1084.	5.0	0
967	Inhalable pH-responsive DNA tetrahedron nanoplatform for boosting anti-tumor immune responses against metastatic lung cancer. Biomaterials, 2023, 301, 122283.	11.4	2
968	Non-Polio Enterovirus C Replicate in Both Airway and Intestine Organotypic Cultures. Viruses, 2023, 15, 1823.	3.3	4
969	Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases. Expert Opinion on Drug Delivery, 2023, 20, 1085-1095.	5.0	1
970	Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization. Cells, 2023, 12, 2057.	4.1	1
971	Nanotechnology of inhalable vaccines for enhancing mucosal immunity. Drug Delivery and Translational Research, 0, , .	5.8	0
972	Nanovaccines: A game changing approach in the fight against infectious diseases. Biomedicine and Pharmacotherapy, 2023, 167, 115597.	5.6	7
973	Supercritical fluid technology: A game-changer for biomacromolecular nanomedicine preparation and biomedical application. Chinese Chemical Letters, 2023, , 109169.	9.0	1
974	Inhaled drug delivery: Past, present, and future. Nano Today, 2023, 52, 101942.	11.9	3
977	Aerosol Dosage Forms. , 2024, , 319-339.		0
978	Inhalation of panaxadiol alleviates lung inflammation via inhibiting TNFA/TNFAR and IL7/IL7R signaling between macrophages and epithelial cells. Journal of Ginseng Research, 2023, , .	5.7	0
980	Chitosan-based pulmonary particulate systems for anticancer and antiviral drug carriers: A promising delivery for COVID-19 vaccines. Results in Chemistry, 2023, 6, 101146.	2.0	0
981	Protein and peptide delivery through chitin, chitosan, and starch. , 2024, , 169-195.		0
982	Inhalation Pharmacodynamics. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2023, 36, 275-280.	1.4	0

#	ARTICLE	IF	CITATIONS
983	Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	4
984	Use of Closed System Transfer Devices (CSTDs) with Protein-Based Therapeutic Drugsâ€”A Non-Solution for a Non-Problem?. Journal of Pharmaceutical Sciences, 2024, 113, 298-305.	3.3	1
985	Inhaled pulmonary surfactant biomimetic liposomes for reversing idiopathic pulmonary fibrosis through synergistic therapeutic strategy. Biomaterials, 2023, 303, 122404.	11.4	0
986	Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis. Bioactive Materials, 2024, 33, 262-278.	15.6	1
987	Long-acting inhaled medicines: Present and future. Advanced Drug Delivery Reviews, 2024, 204, 115146.	13.7	1
988	Nano vs Resistant Tuberculosis: Taking the Lung Route. AAPS PharmSciTech, 2023, 24, .	3.3	0
990	Emerging delivery approaches for targeted pulmonary fibrosis treatment. Advanced Drug Delivery Reviews, 2024, 204, 115147.	13.7	1
991	The Utilization of Plant-Material-Loaded Vesicular Drug Delivery Systems in the Management of Pulmonary Diseases. Current Issues in Molecular Biology, 2023, 45, 9985-10017.	2.4	0
992	Nitric oxide-assisted mucus-walking zwitterionic nanocomplexes for synergistic treatment of severe respiratory infectious disease. Materials Today, 2023, , .	14.2	0
993	Inhaled Medicines for Targeting Non-Small Cell Lung Cancer. Pharmaceutics, 2023, 15, 2777.	4.5	0
994	A novel nanobody broadly neutralizes SARSâ€”CoVâ€”2 via induction of spike trimer dimers conformation. Exploration, 0, , .	11.0	1
995	Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature, 2023, 624, 630-638.	27.8	4
996	Exploring the role of electrostatic deposition on inhaled aerosols in alveolated microchannels. Scientific Reports, 2023, 13, .	3.3	0
997	Efficient pulmonary fibrosis therapy via regulating macrophage polarization using respirable cryptotanshinone-loaded liposomal microparticles. Journal of Controlled Release, 2024, 366, 1-17.	9.9	0
998	ACE2 Receptorâ€”Targeted Inhaled Nanoemulsions Inhibit SARSâ€”CoVâ€”2 and Attenuate Inflammatory Responses. Advanced Materials, 2024, 36, .	21.0	0
999	Practical Considerations in Dose Extrapolation from Animals to Humans. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2024, 37, 77-89.	1.4	0
1000	Pulmonary Delivery of Antibody for the Treatment of Respiratory Diseases. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 21-51.	0.1	0
1001	Pharmacokinetics of Inhaled Medications â€” What Do We Know About Biological Macromolecules?. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 193-213.	0.1	0

#	ARTICLE	IF	CITATIONS
1002	Delivery system of phenolic compounds for the treatment of lung cancer. , 2024, , 125-145.		0
1003	Inhalable point-of-care urinary diagnostic platform. Science Advances, 2024, 10, .	10.3	1
1004	The quest to deliver high-dose rifampicin: can the inhaled approach help?. Expert Opinion on Drug Delivery, 2024, 21, 31-44.	5.0	0
1005	Oscillating high aspect ratio micro-channels can effectively atomize liquids into uniform aerosol droplets and dial their size on-demand. Lab on A Chip, 2024, 24, 1676-1684.	6.0	0
1006	Design Strategies of Dry Powders for Pulmonary Delivery of Pharmaceutical Peptides. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 1-20.	0.1	0
1007	Lipidated brush-PEG polymers as low molecular weight pulmonary drug delivery platforms. Expert Opinion on Drug Delivery, 2024, 21, 151-167.	5.0	0
1008	Using Dry Dispersion Laser Diffraction to Assess Dispersibility in Spheronized Agglomerate Formulations. AAPS PharmSciTech, 2024, 25, .	3.3	0
1009	Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities. Expert Opinion on Drug Discovery, 2024, 19, 493-506.	5.0	0
1010	Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives. Journal of Drug Delivery Science and Technology, 2024, 94, 105517.	3.0	0
1011	Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale [®] system: A first evaluation in humans. European Journal of Pharmaceutical Sciences, 2024, 196, 106742.	4.0	0
1012	Inactivation of virions in host particles in air using 222- and 254-nm UV: Dependence of shielding on particle size and UV wavelength. Aerosol Science and Technology, 2024, 58, 512-535.	3.1	0
1013	The Processing Space of the Spray-Dried Mannitol-Leucine System for Pulmonary Drug Delivery. Pharmaceutics, 2024, 16, 398.	4.5	0
1014	Advances in Pulmonary Protein Delivery Systems. Advanced NanoBiomed Research, 0, , .	3.6	0
1015	Nebulization and <i>In Vitro</i> Upper Airway Deposition of Liposomal Carrier Systems. Molecular Pharmaceutics, 2024, 21, 1848-1860.	4.6	0
1016	Poly(malic acid)-budesonide nanoconjugates embedded in microparticles for lung administration. Drug Delivery and Translational Research, 0, , .	5.8	0